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Preface 
This thesis was originally submitted to the University of Newcastle upon Tyne for 
consideration for the degree of doctorate of medicine in June 2003. Due to problems with 
the external examiner a delay of two years occurred before an incomplete examination of 
the thesis took place. This lead to an initial decision by the university not to award the 
degree and an appeal against the examiners decision was advised. The appeal was 
successful and re-examination of the thesis was suggested. The delays introduced by this 
process have rendered much of this thesis out of date however the author believes that the 
underlying research principles applied in the thesis remain valid. 
The electrophysiology of atrial fibrillation is a rapidly advancing field and many of 
the treatments and theories outlined in this thesis have now moved on. In particular the 
theories concerning the initiation and propagation of atrial fibrillation have changed. Much 
less emphasis is currently being given to the multiple wavelet hypothesis of Moe outlined 
in this thesis. (l) Recent observations of spontaneous initiation of atrial fibrillation by 
ectopic beats originating in the pulmonary veins has lead to an increased interest in the 
concept of altered automaticity and re-entry leading to atrial fibrillation. Haissagueffe et al 
have lead the way in this field showing that ectopic foci within the pulmonary veins are 
involved in "triggering" many episodes of atrial fibrillation. (2) These observations have 
been put to clinical use by electrophysiologists around the world who have developed 
techniques to isolate these foci. Pappone et al have shown that by using a technique of 
circumferential radiofrequency ablation of pulmonary vein ostia around 85% of patients 
can be rendered free of atrial fibrillation. (3) They reported a very low complication rate 
with no initial thromboembolic complications or significant pulmonary vein stenosis. 
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These impressive results have lead some experts to advocate the use of radiofrequency 
pulmonary vein isolation as a first line therapy for atrial fibrillation. However this remains 
a subject of much debate in part due to the relatively small number of centres currently 
performing what is a time consuming, costly and relatively complex procedure coupled 
with the inability of other centres to achieve similar success rates. Therefore despite 
growing numbers of patients being treated by means of pulmonary vein isolation year on 
year the mainstay of treatment for most patients remains a choice between either attempted 
rhythm control with DC cardioversion and/or drug therapy or ventricular rate control and 
anticoagulation for stroke prophylaxis. 
The "AFFIRM" Study 
Tbroughout this thesis reference is made of the Atrial Fibrillation Follow-up 
Investigation of Rhythm Management (AFFIRM) Study. (4) The AFFIRM study was 
underway at the original time of writing this thesis and its results were eagerly anticipated. 
It was widely predicted that this study would once and for all show that a strategy of 
attempting to maintain sinus rhythm, in patients with chronic atrial fibrillation, would 
provide a survival advantage. The study randomised just over four thousand patients aged 
65 and over to either a rhythm control strategy (2033 patients) or a strategy involving rate 
control and anticoagulation (2027 patients). Rhythm control was attempted with DC 
cardioversion as deemed necessary by the treating physician along with the administration 
of one or more of amiodarone, disopyramide, flecanide, moricizine, procainamide, 
propafenone, quinidine, sotalol or dofetilide. Rate control was said to be achieved when the 
ventricular rate was less than 80 beats per minute at rest or 100 beats per minute during a 
six minute walk test. The permitted therapies to achieve rate control were beta blockers, 
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calcium channel blockers, and digoxin either alone or in combination. Patients failing two 
attempts at drug therapy could proceed to appropriate non-pharmacological therapy. Both 
groups were initially treated with warfarin but this could be stopped in the rhythm control 
group following four weeks of sinus rhythm. The results of the study surprised many with 
the death rate for the rhythm control group (23.8%) being higher than that of the rate 
control group (21.3%, p=0.08). This unexpected result coupled with a higher hospital 
admission rate for the rhythm control group has lead many physicians to question the 
appropriateness of a routine use of a rhythm control strategy. They argue that rate control 
with anticoagulation should be the first line management with attempted rhythm control 
being reserved for those patients who remain symptomatic despite adequate rate control or 
are intolerant of rate control medication. 
Even allowing for the many advances made since the original submission of this 
thesis the clinical question that it attempted to answer remains relevant. Due in part to the 
high prevalence of atrial fibrillation the vast majority of patients continue to be managed 
by a combination of primary care physicians and district general cardiologists with the 
newer ablation techniques currently limited to only a small percentage of patients with 
highly symptomatic atrial fibrillation. The treatment of atrial fibrillation therefore remains 
largely a choice between rhythm control or rate control plus anticoagulation. The question 
of whether or not to consider an attempt at DC cardioversion in an individual patient 
remains a frequent one and to date there is still no definitive means of detennining who 
will benefit from DC cardioversion. 
Abstract 
Aim: Despite atrial fibrillation being the most commonly occurring sustained cardiac 
arrhythmia its treatment remains the subject of great debate. DC cardioversion is a 
treatment option often used to return normal cardiac function. We aimed to assess relapse 
rates following DC cardioversion and to determine whether transoesophageal 
echocardiography, P wave signal averaged electrocardiography or heart rate variability 
measurements had a role in identifying patients likely to relapse to atrial fibrillation. 
Methods: Patients who were referred for DC cardioversion of chronic non-valvular atrial 
fibrillation were enrolled into the study. Transoesophageal echocardiography was 
performed in order to measure left atrial size, left atrial appendage area, and flow velocity 
within the left atrial appendage, left upper pulmonary vein and across the mitral valve. 
Patients in whom cardiac thrombus had been excluded proceeded to DC cardioversion. 
Those patients who achieved sinus rhythm had ap wave signal averaged electrocardiogram 
recorded one hour following the procedure. At forty eight hours those patients remaining in 
sinus rhythm had a second p wave signal averaged ECG recorded and a Holter recording in 
order to determine heart rate variability. Patients were reviewed at three and six months for 
relapse to atrial fibrillation. 
Results: DC cardioversion was initially successful in 66 of the 81 patients (8 1 %). At 48 
hours 23 patients (35%) had relapsed to AF. No PSAECG measurement differed 
significantly between these groups. Mean mitral valve flow velocity differed significantly 
between those who relapsed to AF within 48 hours and those who remained in sinus 
rhythm (SR group = 83.98cm/s, AF group 71.05cm/s, p=0.048). At three months 48 
patients had relapsed to AF (73%) this increased to 51 patients (77%) at six months. No 
significant difference was observed in any of the TOE, PSAECG or HRV measurements in 
these groups. 
Conclusion: No PSAECG or HRV variable helped to predict long term success. TOE 
measurement of mitral valve flow velocity may allow prediction of early relapse. DC 
cardioversion without antiarrhythmic prophylaxis leads to a high relapse rate. 
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1 INTRODUCTION 
1.1 A Brief History 
Atrial fibrillation is by no means a new phenomenon, as long ago as 2000 years BC 
Huang Ti Nei Ching Su Wen, the emperor physician who ruled China, wrote of a condition 
associated with an irregular pulse and a poor outcome. It is possible that he was referring 
to atrial fibrillation when he wrote "when the pulse is irregular and tremelous and the beats 
occur at intervals, then the impulse of life fades. "(5) 
Closer to home atrial fibrillation appears to have gone unrecognised for a 
considerable time. William Harvey was one of the first western physicians to recognise 
that an irregular pulse was associated with ill health. In 1628 he wrote about "fibrillation of 
the auricles" and its impact on the health of a patient in his care. Reliable diagnosis of 
atrial fibrillation was only made possible following the invention of technology capable of 
electrically recording the impulses that lead to mechanical activity within the heart. 
Thomas Lewis produced recordings from patients with irregular rhythms that are now 
known to be of atrial fibrillation at University College London in 1900. (6) However it was 
not until further advances in biochemical techniques took place that the 
electrophysiological significance of these recordings could be appreciated. 
1.2 Electrophysiology Of Atrial Fibrillation 
Despite extensive research the precise electrophysiological basis of atrial 
fibrillation still remains unclear. There are however two main theories regarding the 
propagation of atrial. fibrillation, these are the "multiple wavelet theory" and the "re-entry 
theory". In the first of these theories, the "multiple wavelet theory", disorganised atrial 
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activity due to multiple small wavelets which propagate in a random haphazard manner 
within the atria are thought to underlie the initiation of the arrhythmia. This lack of ordered 
electrical depolarisation leads in turn to a lack of organised atrial contraction. Moe et al 
used a computer model to predict that a minimum of between 23 to 40 wavelets are 
required to allow atrial fibrillation to propagate. (7) Allesie et al studied the same 
phenomena in the heart of a dog and found that fewer wavelets than previously predicted 
were required. (8) Here atrial fibrillation was demonstrated with as few as 4 wavelets. 
In the second theory the "re-entry theory", originally proposed by Lewis in 1925, a 
single high frequency re-entrant source is thought to give rise to fibrillatory conduction. (9) 
More recently Schuessler et al studied this phenomena in the isolated right atria of 
dogs. (10) They demonstrated that as the acetylecholine concentration within the heart was 
increased the activation pattern within the atria changed. The previously multiple re-entrant 
circuits coalesced to form a single relatively stable, high frequency re-entrant circuit that 
resulted in fibrillatory conduction as seen in atrial fibrillation. Further work is clearly 
required to determine whether one of these theories, or a combination of the two, hold the 
key to the electrophysiological basis of atrial fibrillation. 
1.3 Diagnosis Of Atrial Fibrillation 
Atrial fibrillation can be reliably diagnosed in the majority of cases from a standard 
12 lead surface electrocardiogram. The P wave normally detected on the electrocardiogram 
during atrial contraction is replaced by irregular baseline deflections called f waves. These 
f waves occur at a rate varying between 350 and 600 per minute. Thankfully patients with 
atrial fibrillation rarely have ventricular rates as high as 350 beats per minute. The reasons 
for this discrepancy are two fold. Firstly the atrioventricular nodal refractory period is such 
that depolarisation at this rate is not possible in a normally functioning node. The second 
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reason is that the fibrillatory wavelets are involved in collisions with one another and this 
results in cancellation of many electrical impulses. The random nature of these collisions 
also causes the ventricular rhythm to be irregularly irregular in nature, thus giving rise to 
the characteristic irregularly irregular pulse found in patients with atrial. fibrillation. 
1.4 Classification Of Atrial Fibrillation 
Patients with atrial fibrillation can be classified into one of three groups depending 
on the nature of the arrhythmia. The first group of patients are those in whom the 
arrhythmia will spontaneously revert to normal sinus rhythm only to recur at a later date. 
Patients with this so called "paroxysmal" form of atrial. fibrillation may have anything 
from very infrequent brief episodes of atrial fibrillation to prolonged, frequent episodes 
which become almost continuous. The second group of patients are those in whom the 
arrhythmia persists only until some form of treatment is commenced and following which 
normal sinus rhythm is restored. These patients are said to have persistent atrial fibrillation. 
The third class of patients are those in whom atrial fibrillation continues unabated despite 
treatment. These patients are said to have permanent atrial fibrillation. It should be 
remembered that this classification is not as rigid as it first appears, patients in the 
paroxysmal group often have an increasing frequency of episodes leading to persistent or 
permanent atrial fibrillation. Similarly patients who at first appear to have persistent atrial 
fibrillation may with treatment change to having paroxysmal episodes. 
1.5 Epidemiology Of Atrial Fibrillation 
Atrial fibrillation is now the most frequently encountered cardiac arrhythmia in the 
western world. In the United States it is estimated that approximately two million people 
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have atrial fibrillation at any one point in time. It is therefore no surprise that hospital stays 
for atrial fibrillation far outweigh those for any other cardiac arrhythmia. (5) 
Although the vast majority of cases of atrial fibrillation occur in adult life cases 
have been reported in all age groups. In the foetus; and neonate atrial fibrillation is nearly 
always a result of an accessory pathway and resolution usually occurs within the first year. 
In the western world atrial fibrillation in adolescence is rare and is usually reported in 
association with dilated or hypertrophic cardiomyopathy, intracardiac tumours, muscular 
dystrophy and very occasionally with hyperthyroidism(l 1) In developing countries atrial 
fibrillation in adolescence is more common often being a consequence of rheumatic 
valvular disease. 
The overall prevalence of atrial fibrillation in adults increases with increasing age, 
with some 0.5% of the population aged between 50 and 59 being affected. This figure 
rising to nearer 9% for patients aged between 80 and 89. (12) Using data collected in the 
Framingham study it is estimated that there is a cumulative 22-year incidence of atrial 
fibrillation of 21.9 per 1000 men (2.19%) and 17.1 per 1000 women (1.71 %). Similar 
figures have been reported for the U. K. (13) In patients without rheumatic heart disease the 
2-year incidence of atrial fibrillation is lower with some 0.04% of men and 0.0 1% of 
women aged between 30 and 39 developing the arrhythmia. Again the incidence rises 
sharply with advancing age. In the age group 80 to 89 the 2-year incidence rises to 4.6% 
for men and 3.6% for women. Despite having lower incidence figures the majority of 
patients with atrial fibrillation are female. This can be explained by the longer life 
expectancy of women coupled with the bias towards developing atrial fibrillation in later 
life. 
These figures obviously have marked implications for an ageing western 
population. As the percentage of the population surviving into the eighth decade increases 
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the number ofcases of atrial fibrillation are also expected to increase. This will have 
important implications both flor patients and health care providers placing an increased 
strain on healthcare resources. 
1.6 Aetiology Of Atrial Fibrillation 
The causes of atrial fibrillation can be broadly divided into two groups as shown in 
the table below. In the first group atrial fibrillation is a manit'estation ofstructural heart 
disease. In the second atrial fibrillation occurs as a result ol'a systernic illness or disease 
process in the absence ol'structural heart disease. 
Structural "cart Disease Systemic Disease 
I lypertensive heart disease Major infections 
(especially respiratory) 
Coronary artery disease Thyroid disease 
VaIvular heart disease Severe electrolyte disturbance 
Cardiomyopathy Malignancy (especially thoracic) 
Cardiac surgery Alcohol 
Pericarditis Sarcoldosis 
Congenital heart disease Phaeochrornocytorria 
Amyloidosis 
Non cardiac surgery 
Table I Causes ofatrial fibrillation 
Mis grouping does not however include those individuals in whom structural heart 
disease is absent and no trigger event or illness ean be determined. These patients. said to 
have "lone" atrial fibrillation, can account for as many as 29% of patients presenting with 
atrial fibrillation. ( 14) 
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These two groups also differ in terms of the predominant pathological changes 
found within the heart muscle. Myosite fibrosis is more commonly found in patients with 
atrial fibrillation secondary to structural heart disease. However this is rarely seen in atrial 
fibrillation secondary to a non cardiac systemic illness. 
Atrial fibrillation may also occur as the only clinical manifestation of a rare genetic 
disorder. Brugada et al recently identified three families in northern Spain in which 21 of 
49 family members had atrial fibrillation. DNA sequencing revealed a mutation within the 
10q chromosome in the affected individuals. They concluded that since no other cause for 
this clustering of patients with atrial fibrillation could be identified the mutation of I Oq22- 
q24 was responsible for the affhythmia. (l 5) To what extent genetic susceptibility accounts 
for lone atrial fibrillation in other populations is unknown. 
The aetiological trends seen in patients presenting with atrial fibrillation have 
changed over the last decade. Since the Framingham data was first published the 
proportion of patients presenting with atrial fibrillation secondary to valvular heart disease 
has declined. In particular a marked decline has been seen in the number of cases of atrial 
fibrillation secondary to rheumatic heart disease. In a study of French general practices 
Levy et al showed that of 756 patients with atrial fibrillation, 70% were thought to be 
secondary to structural heart disease. (14) Of this group the commonest cause was 
hypertension (39.4%), coronary heart disease comprised some 16.6%, and myocardial 
disease 15.3%. Rheumatic valvular disease, although less common than in previous 
studies, was still an important risk factor being implicated as a causal factor in 25% of 
women with atrial fibrillation but only 8% of men. 
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1.7 Clinical Presentation 
Patients with atrial fibrillation present with a varied range of symptoms and as such 
may present to doctors practising in all fields of medicine. Presentation is influenced by a 
number of factors including the premorbid cardiac function, coexistent medical problems, 
the ventricular rate and the patients perceptions of these factors. A number of patients with 
atrial fibrillation will present to the emergency department with circulatory collapse. This 
is most often secondary to a rapid ventricular rate or due to complications such as 
thromboembolic stroke. More commonly presentation takes a less acute form occurring 
due to symptoms including palpitations, breathlessness, fatigue or a combination of these. 
Lok et al showed that 42.3% of patients admitted to hospital with a diagnosis of atrial 
fibrillation had palpitations as a first symptom. (16) Other symptoms reported included 
breathlessness (3 8.1 %) and symptoms associated with worsening heart failure (16.4%). 
Levy et al found similar results in general practice with palpitations being present in 
54.1 %, and breathlessness in 44.4%. In this series 11.4% of patients were asymptornatic, 
being identified on routine screening. (14) 
1.8 Course Of Untreated Atrial Fibrillation 
The natural history of atrial fibrillation vanes considerably between patients. As 
previously discussed atrial fibrillation of acute onset may spontaneously terminate, may 
terminate and recur in a paroxysmal fashion or may continue unabated and become chronic 
in nature. 
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1.8.1 The Electrophysiology Of Chronicity 
It has been shown in animal models that artificially induced atrial fibrillation 
becomes more resistant to termination with increasing duration of the arrhythmia. This 
phenomenon of atrial fibrillation begetting atrial fibrillation has been further supported by 
epidemiological evidence in humans. (17) The physiological mechanisms underlying this 
tendency towards chronicity are under investigation. One theory, which has gained 
support, is that a progressive decrease in the atrial refractory period occurs with increasing 
duration of the arrhythmia. This allows wavelets of electrical activity to propagate thus 
ensuring the continuation of the arrhythmia. Wijffels et al were among the first to show 
that in a goat model the effective atrial refractory period shortened following a period of 
artificially induced atrial fibrillation. (I 8) Following on from this observation the same 
investigators attempted to elucidate the exact stimulus for this electrical remodelling. The 
potential involvement of the autonomic nervous system was measured by studying the 
effect of atropine and propanolol on the atrial refractory period both prior to and following 
atrial fibrillation. No relationship could be demonstrated between autonomic nervous 
system activity and electrical remodelling. Similarly infusing glibenclamide, a blocker of 
ATP regulated potassium channels to produce ischaernia had no effect on the atrial 
refractory period. This led to the conclusion that ischaemia of the atrial myocardium was 
not the trigger. (8) 
Increased levels of atrial naturetic factor have been demonstrated during atrial 
tachyarrhythmias and this has been suggested as a possible precursor to remodelling*(19) 
However measurements of the duration of the effective atrial refractory period following 
infusion of high levels of atrial naturetic factor have failed to provide support for this 
theory. (20) Data from the same study suggested that the changes seen in effective atrial 
refractory period were as a result of an increase in the rate of electrical activation of the 
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myocytes. The shortening of effective refractory period being most pronounced in those 
animals which had undergone high rates of atrial pacing early in the experiment. Yu et al 
showed that a similar rate related electrical remodelling could be demonstrated in 
humans. (21) Here the effective atrial refractory period was measured in human volunteers 
before and after atrial pacing at different rates. The effective atrial refractory period was 
significantly shorter following high rates of atrial pacing. The cellular changes responsible 
for this shortening of the atrial refractory period are not fully understood. Theories 
involving a decrease in calcium influx(22) into cells and upregulation of potassium 
channels(23) have been put forward and are currently under investigation 
1.8.2 Spontaneous Sinoconversion 
Atrial electrical remodelling with perpetuation of the arrhythmia is not the only 
outcome possible for a patient presenting with atrial fibrillation. As mentioned previously 
patients with a first episode of atrial fibrillation may spontaneously revert to sinus rhythm 
and have no further episodes. 
Various rates of spontaneous conversion to sinus rhythm have been reported. 
Donovan et al reported a 35% spontaneous conversion rate at 2 hours in patients presenting 
with atrial fibrillation of less than 72 hours duration. (24) Capucci et al reported similar 
figures at eight hours following onset with some 39% returning to sinus rhythm. (25) Dell 
Orfano, et al. compared hospital charges for patients who spontaneously converted to sinus 
rhythm to those who required electrical or pharmacological cardioversion. (26) They found 
that spontaneous cardioversion was associated with significantly lower hospital costs. This 
coupled with a high spontaneous sinoconversion rate of 65% prompted them to suggest 
that a "wait and see" strategy should be employed. Using this strategy patients are 
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observed for a forty-eight hour period prior to rhythm management being attempted. They 
suggested that this would save money and physician time. 
The mechanism underlying this self-termination is thought to be a lack of 
shortening of the atrial refractory period. This coupled with a reduction in propagating 
wavelets due to collisions leads to the number of wavelets falling below the number 
required to maintain the arrhythmia. 
1.8.3 Paroxysmal Atrial Fibrillation 
The previous two outcomes represent either end of a spectrum with a third outcome 
spanning the middle. Here a patient's first episode of atrial fibrillation may terminate only 
to recur at a later date. This episodic pattern of atrial fibrillation is termed paroxysmal 
atrial fibrillation. The electrophysiology of paroxysmal atrial fibrillation is more complex. 
Initiation of atrial fibrillation is thought to occur in the usual way with the number of 
propagating wavelets reaching the required number to give rise to fibrillation of the atria. 
However the effective atrial refractory period does not continually shorten but instead 
somehow lengthens. This in turn leads to a reduction in the number of wavelets until the 
required number to maintain atrial fibrillation no longer exist and the arrhythmia 
terminates. (27) This sequence of events is then thought to recur leading to paroxysms, 
which may be frequent in nature. 
1.9 Complications Of Atrial Fibrillation 
The major complications of atrial fibrillation include thromboembolic events, 
haemodynamic'dysfunction and cardiornyopathy. All of which lead to a substantial 
increase in both morbidity and mortality for patients with atrial fibrillation as compared to 
normal subjects. 
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1.9.1 Thromboembolic Events 
Atrial fibrillation is the commonest cardiac condition to increase the risk of a 
systemic thromboembolism. During atrial fibrillation atrial contraction is reduced to such 
an extent that laminar flow of blood is lost. Turbulent blood flow and stasis occur 
increasing the potential for clot formation in the atria and the atrial appendages. Embolism 
from these sites is not an uncommon occurrence most commonly presenting with the 
symptoms of an acute ischaernic stroke. Epidemiological studies have shown that 
approximately 15 to 20 percent of all patients who present to accident and emergency 
departments with symptoms due to an acute stroke will be in atrial fibrillation. This figure 
is much higher for older age groups with 36 percent of stroke patients over 80 years of age 
having atrial fibrillation at the time of presentation. Furthermore patients presenting with 
an acute stroke and atrial fibrillation have been shown to have a mortality which is three 
times greater than patients who are in sinus rhythm at the time of their stroke after allowing 
for other variables. (28) 
The relative stroke risk associated with atrial. fibrillation depends on the underlying 
cause of the arrhythmia and various patient factors. The risk is greatest for atrial fibrillation 
complicating rheumatic heart disease in which the relative risk approaches 17.5 times that 
of patients without atrial fibrillation. (12) In patients who have chronic atrial fibrillation but 
no evidence of rheumatic heart disease the relative risk of stroke is estimated at 6.9 times 
that of nonnal subjects. Several independent risk factors for thromboembolic 
complications in atrial fibrillation have also been identified. Pooled data from randomised 
primary prevention trials has shown that the stroke risk in patients with atrial. fibrillation is 
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increased further by the presence of hypertension (relative risk 1.6), diabetes mellitus 
(relative risk 1.7) and previous stroke or transient ischaernic attack (relative risk 2.2). 
These figures take into account only those patients who have a clinically evident 
cerebrovascular event. Screening of individuals with atrial fibrillation but no clinical 
symptoms relating to cerebrovascular disease has shown that so called "silent" cerebral 
infarction is present in a substantial proportion. Ezekowitz et al, screened 516 patients with 
atrial fibrillation by means of computed tomography and found evidence of silent cerebral 
infarction in 14.7% of patients with no prior history of stroke. (29) The major weakness of 
this study was that it did not contain a control group in whom atrial fibrillation was absent. 
This was not the case in the study conducted by van Laturn et al who studied the CT scans 
of 985 patients with non valvular atrial fibrillation and compared them with similar scans 
in 2987 patients without atrial fibrillation. They reported that the incidence of cerebral 
infarcts, which could not be ascribed to the patients' current neurological symptoms, was 
significantly higher in patients with atrial fibrillation group (20% Vs 15%; OR 1.5; 95% CI 
1.2-1.8). (30) Whether this increase in silent ischaernic episodes leads to a clinically 
detectable deterioration in mental function has been investigated by 0' Connell and 
colleagues. (3 1) They compared cognitive function in 54 patients with non-valvular atrial 
fibrillation to age and sex matched controls. None of the patients included in the study had 
a history of clinically apparent transient ischaemic episodes or stroke. They found that 
patients with atrial fibrillation attained lower scores in all tests when compared to those 
without the arrhythmia. A similar association was noted in the Rotterdam Study in which a 
large cohort of patients were screened for the presence of dementia, cognitive impairment 
and atrial fibrillation. (32) Dementia was found to be more than twice as common in 
patients with atrial fibrillation, with the Alzheimer's disease subtype showing the strongest 
association. 
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The risk of thromboembolic complications with paroxysmal atrial fibrillation is less 
clear cut. Several studies have attempted to define the risk of stroke with paroxysmal atrial 
fibrillation. Varying incidences from between 2 percent per year(33) and 5.7 percent(34) 
per year have been reported. This discrepancy in rates may in part be due to the 
heterogeneous nature of paroxysmal atrial fibrillation and the difficulty in comparing 
groups with regard to the duration and frequency of arrhythmic episodes. What is clear is 
that paroxysmal atrial fibrillation increases stroke risk. This has prompted many physicians 
to suggest that thromboembolic prophylaxis should be prescribed in a similar manner as 
for chronic atrial fibrillation. 
1.9.2 Haemodynamic Dysfunction 
There are several mechanisms in which atrial fibrillation may lead to clinically 
apparent haemodynamic dysfunction. In the first a rapid ventricular rate results in a 
decrease in the time available for ventricular filling. This causes particular problems for 
individuals whose diastolic filling has already been compromised by co existing pathology 
such as mitral stenosis or abnormalities in ventricular relaxation time and pulmonary 
oedema results. A second consequence of a rapid ventricular response is an increase in 
ventricular oxygen demand, with the potential to precipitate an acute coronary syndrome 
and ultimately infarction of vulnerable myocardium. 
The loss of atrial transport per se seen with atrial fibrillation and the subsequent 
decrease in cardiac output may be sufficient to cause symptoms of heart failure. This is 
more troublesome in patients who already have a decrease in their cardiac output due to 
other pathology such as previous myocardial infarction or hypertensive heart disease. In 
these patients atrial. contraction is required to maintain adequate ventricular filling and 
cardiac output. 
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All of these haernodynamic changes may be transient in paroxysmal atrial 
fibrillation, causing few symptoms, but in chronic atrial fibrillation they are often disabling 
requiring acute treatment and frequently leading to hospitalisation. 
1.9.3 Cardiomyopathy 
Tachycardia induced cardiomyopathy refers to the syndrome in which rapid 
ventricular rates, when left untreated, predispose the patient to changes within the 
myocardium resulting in ventricular remodelling and a decrease in ventricular systolic 
function. These changes are initially reversible and restoration of sinus rhythm or control 
of the ventricular rate either chemically or mechanically will bring about restoration of 
normal systolic function. (35) However if the ventricular rate remains uncontrolled the 
remodelling process becomes irreversible with a continued decline in cardiac function. The 
cellular basis for this decrease in myocyte function remains largely unexplained. Eble et al 
showed that in pigs tachycardia induced cardiornyopathy was associated with an increase 
in myocyte cytoskeletal protein and a decrease in myocyte contractile function. However 
no change was observed in contractile protein content or myocyte mRNA. (36) Whether 
similar changes are responsible for the reduced contractile function in humans is not clear. 
1.9.4 Mortality 
The impact of atrial fibrillation on mortality is often not appreciated by either 
patients or clinicians. Several well designed follow up studies have shown that far from 
being a benign cardiac arrhythmia atrial fibrillation confers a marked survival 
disadvantage. Mortality data from the Framingham study shows that in the age group 55 to 
74 years, after 10 years, 61.5% of men with atrial. fibrillation had died compared with 3 0% 
of those without the arrhythmia. In women 57.6% of those with atrial fibrillation had died 
as compared with 20.9%. Another way of expressing this is to look at median survival 
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which gives an indication of how much longer a person without atrial fibrillation will live 
when compared to age and sex matched subjects with atrial fibrillation. Data from the 
same study shows a median survival for men aged 55 to 64 with atrial fibrillation to be 
12.6 years compared to 18.1 years for those without atrial fibrillation. For women of the 
same age the figures were even more striking with a median survival of 12.1 years with 
atrial fibrillation compared to 21.3 years without. The odds ratios for these groups are such 
that the increased risk of death is 1.5 for men with atrial fibrillation (95% CI, 1.2 to 1.8) 
and 1.9 for women (95% Cl, 1.5 to 2.2). (37) The identification of this marked survival 
disadvantage has prompted renewed interest in the treatment of atrial fibrillation with the 
goal of eliminating the survival disadvantage. 
1.10 Quality Of Life And Atrial Fibrillation 
It is only in recent years that quality of life has been recognised as an important 
outcome measure in the treatment of atrial fibrillation. Because of this there is relatively 
little data available on how atrial fibrillation, and its subsequent treatment, effects quality 
of life. Those studies that do exist often fail to use properly validated tools to measure 
quality of life making interpretation difficult. The patients included in these studies also 
fail to reflect the vast majority of patients with atrial fibrillation instead concentrating on 
individuals who are highly symptomatic and either intolerant of medication or resistant to 
it. In one study follow up interviews were conducted with patients following either 
radiofrequency or direct current catheter ablation of the AV node. An improved quality of 
life was reported in 80% following direct current ablation and 84% of those undergoing 
radiofrequency ablation. (38) The questions asked to assess quality of life in this study were 
not specified making comparison with other patient groups impossible. 
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Two large scale prospective trials are currently underway to try and provide 
information on quality of life in more typical patients with atrial fibrillation. The Atrial 
Fibrillation Follow-up Investigation of Rhythm Management is a prospective trial of over 
5000 patients who will be randomised to either rate control or antiarrhythmic drug 
treatment with quality of life a secondary end point using validated questionnaires. (4) The 
International Quality of Life Investigators Trial similarly uses validated questionnaires to 
assess quality of life in patients with atrial fibrillation but in this study a control group will 
also be assessed. Early results from this group have suggested that patients with 
paroxysmal atrial fibrillation who have frequent episodes may have a lower quality of life 
than patients with chronic atrial fibrillation. (39) 
1.11 Treatment Strategies 
Numerous different treatment strategies are currently employed in an attempt to 
reduce the mortality and morbidity associated with chronic atrial fibrillation. This is a 
reflection of the fact that none of the currently available strategies is ideal for all patients 
with atrial fibrillation, each having points in its merit but also carrying risks or side effects. 
Broadly these strategies fall into two main categories, those where ventricular rate control 
with thromboembolic prophylaxis is the main aim, and those aimed at restoring normal 
sinus rhythm. Although logically restoration of sinus rhythm, the physiological state, 
where possible would appear to be the most desirable end point. There is currently little 
evidence to separate these regimes in terms of mortality data. It is hoped that the AFFIRM 
study which is currently underway will provide further clarification. (40) The selection of 
which treatment regime to use should be carried out on an individual patient basis taking 
into account the relative risks both from the arrhythmia and the treatment and any 
anticipated gain. Patients who present with life threatening haemodynamic compromise 
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require urgent restoration of sinus rhythm and the most reliable means of achieving this is 
by external DC cardioversion. For patients presenting with a more stable picture the 
decision on which treatment regime to employ is usually less urgent and less clear cut. 
Both treatment strategies can be achieved either pharmacologically or by means of 
electrophysiological or surgical intervention. 
1.11.1 Medical therapy 
1.11.1.1 Ventricular rate control 
Ventricular rate control is often used when restoration of sinus rhythm has proved 
impossible or as a temporary measure prior to attempting rhythm control. The main aim of 
treatment is to reduce the ventricular response to atrial depolarisation in order to alleviate 
symptoms and to avoid potential complications such as tachycardia induced 
cardiornyopathy. The agents commonly used to achieve this goal include digoxin, beta- 
adrenergic blockers and calcium channel blockers. 
Digoxin may be used intravenously to slow the resting ventricular heart rate in 
highly symptomatic individuals. Its therapeutic effects are not usually apparent until at 
least sixty minutes following administration and its full effect may not be seen for up to six 
hours. Its mild positive ionotropic action makes it an attractive choice for patients with 
congestive cardiac failure and atrial fibrillation. However although digoxin is effective in 
controlling heart rate at rest it has little influence over heart rate during exercise. (41) It has 
been shown to be no better than placebo at converting atrial fibrillation to sinus rhythm 
(42)and there is some evidence suggesting that digoxin may in fact prolong episodes in 
paroxysmal atrial. fibrillation. (43) Despite these limitations digoxin continues to be the 
most commonly prescribed drug for rate control of chronic atrial fibrillation. (44) 
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Beta adrenergic blocking drugs can be used both acutely and long term to control 
ventricular rate. In the acute situation intravenous beta blockade will rapidly control 
ventricular rate but the potential complication of precipitating hypotension or congestive 
cardiac failure must be bome in mind. When given orally beta-blockers will control 
ventricular rate both at rest and during exercise making them an ideal first choice for those 
patients who have no contraindications and can tolerate them. 
Calcium antagonists have become a popular choice for rate control in the United 
States with some 15% of patients with chronic atrial fibrillation taking either diltiazern or 
verapamil. (44) When given intravenously diltiazern has an effect on the ventricular rate 
within a few minutes and a continuous infusion will give satisfactory rate control in the 
majority of patients. (45) Verapamil has been shown to have a similar effect but is less 
widely used. (44) Both drugs have hypotension. as there major side effect occurring in upto 
7.5% of those receiving diltiazern by the intravenous route. (45) Hypotension is less of a 
problem with diltiazern or verapamil when given orally for rate control in chronic atrial 
fibrillation. Here the main concern is the negative ionotropic effect of both agents, which 
limits their use in patients with cardiac failure. 
Combination therapy for rate control is often necessary and the addition of digoxin 
to a beta blocker or calcium antagonist has been shown to give an increase in benefit 
without increasing side effects. (46) 
1.11.1.2 Thromboembolic prophylaxis in chronic atrial fibrillation 
As previously outlined thromboembolism is responsible for a large proportion of 
the increased morbidity and mortality seen in patients with atrial fibrillation. However the 
risk of stroke in patients with atrial fibrillation is not unifon-n and is influenced by several 
other criteria. For example stroke risk increases with increasing age being low in those 
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aged 50-59 with chronic atrial fibrillation but rises to around 30% in similar patients aged 
over 80. (] 2) Using these criteria patients can be divided into high. moderate or low risk 
groups. It is recommended that patients in the high-risk group receive warfarin therapy 
with a target INR of between 2.0 and 3.0 providing no contra indications exist. (47) For 
patients in the low risk group aspirin therapy is recommended. Thromboembolic 
prophylaxis in the moderate risk group is less clear Cut and no clear recommendations exist 
with individual patient and physician prellcrctice determining therapy. The use ot'such 
guidelines in patients with chronic atrial fibrillation has been shown to be both clinically 
effective and to reduce healthcare costs. (48) 
Risk of CVA Presence of one or more of 
Previous stroke or transient ischaernic attack 
Age > 75 years, Hypcrtcrision, Diabetes, 
I ligh Risk Group Coronary heart disease, congestive cardiac 
failure. left ventricular dysfunction. 
Moderate Risk Group Age 65 - 75 with none ofthe above risk factors 
Low Risk Group Age < 65 with none of the above risk factors 
Table 2 Risk ol'('VA 
1.12 Restoration of sinus rhythm 
The theoretical advantages of'restoring sinus rhythm include the elimination of 
symptoms, improved haemodynamics and a reduction in the risk of complications 
including thrornboembolism. Evidence that restoring sinus rhythm confers a survival 
advantage over simple rate control is however lacking at present. The AFFIRM trial which 
is currently in its recruitment stage amis to solve this problem. (4)1 lere patients with 
chronic non-valvular atrial fibrillation are randornly assigned to either rate control and 
thromboembolic prophylaxis or rhythm control with mortality as the primary end point. 
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Despite this lack of evidence most patients with an initial presentation should be 
considered for restoration of sinus rhythm either initially or aller treatment ofthc 
underlying cause. Sinus rhythm may be restored using drug therapy (pharmacological 
cardioversion) electricity (external or internal cardioversion) or by invasive procedures. 
1.12.1 Pharmacological cardioversion 
Currcntly a number ot'dill'crent agents are available in the UK lor the 
pharmacological cardioversion of atrial fibrillation. The Singh Vaughan Williams 
classification is usually used to group these agents by means oftheir biochemical action on 
the cardiac myocyte. (49,50) 
Singh Vaughan Drug Mechanism / action 
Williams Class 
Quinidine, procainamide, Fast sodium channel blockade. 
la disopyrarnide Prolongation of repolarisation. PR 
and QRS duration 
Lignocaine, mexilitine, Fast sodium channel blockade. 
lb phenytom Shorten repolarisation and Q-l' 
interval 
Flecanide, propafenone Fast sodium channel blockade but 
Ic Q'I'minimally changed 
Atenolol, metoprolol, Block beta adrenergic receptors 
esmolol and slow rate 
Armodarone, sotalol Potassium channel blockade and 
prolong repolarisation 
Vcrapamil, diltiazem, Blockade of slow calcium channel 
IV nifedipme 
'Fable 3 Singh Vaughan Williams classification of antiarrhythinic medication. 
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Class I agents were among the first to be used to terminate atrial fibrillation and 
still remain a popular choice in North America. This class of agent has a number of 
potentially troublesome side effects including prolongation of the QT interval and 
subsequent initiation of torsades de pointes. It is also important to be certain of the 
diagnosis as these agents can increase atrioventricular conduction in patients with atrial 
flutter allowing very rapid ventricular rates with disastrous consequences. Quinidine, a 
class la drug, has been shown to be effective in terminating atrial fibrillation but has an 
incidence of proarrhythmic side effects of around 2% and increases mortality compared to 
placebo. (S 1) 
The class Ic drug flecanide has been widely studied for the termination of atrial 
fibrillation and although effective, its use has been limited to those patients who have no 
previous history of ischaernic heart disease. This followed the observation that when given 
to patients who had previously had a myocardial infarction its administration resulted in a 
nearly threefold increase in mortality. (52)- 
Sotalol is a class III antiarrhythmic agent that also has beta blocking properties. It 
has been shown to be at least as effective as quinidine for the termination of atrial 
fibrillation but it too prolongs the QT interval and predisposes to tosades de pointes. (53) 
Because of these side effects initiation of these drugs requires careful monitoring of the QT 
interval with a QT interval of greater than 500msec being an indication for discontinuation 
of the drug. Arniodarone, another a class III agent, has also been shown to be effective in 
cardioverting atrial fibrillation. It has a lower incidence of QT prolongation than the 
previously mentioned agents but has additional side effects that include photosensitivity, 
disturbed thyroid function and pulmonary fibrosis which make its use less desirable in 
patients with little symptoms or underlying thyroid or respiratory disease. Despite this long 
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list of potential side effects arniodarone still remains the most commonly prescribed 
antiarrhythmic for maintenance of sinus rhythm in the United Kingdom. 
1.12.2 External electrical (DC) cardioversion 
External electrical DC cardioversion is an alternative method of restoring sinus 
rhythm that avoids many of the potential side effects of drug therapy. External electrical 
cardioversion is performed using a cardiac defibrillator with the capability of delivering an 
electrical shock between two electrodes with a user-selected energy level. When used to 
cardiovert atrial fibrillation the DC shock must be synchronised to the R wave to reduce 
the risk of precipitating ventricular fibrillation. A short acting general anaesthetic should 
be employed prior to cardioversion and the patient prepared as for any procedure involving 
an anaesthetic. The shock is usually delivered through gel covered pads with the electrodes 
arranged in either an anterior to posterior position or from apex to right anterior on the 
patients thorax. There is some evidence that the anterior-posterior position allows a 
reduction in the energy required to achieve success but despite this the apex-right anterior 
paddle position remains the most widely used. (54) Pressure is applied to the electrodes as 
the shock is delivered in order to reduce thoracic impedance to a minimum. The wavefonn 
of the shock delivered has recently been the centre of interest with biphasic waveforms 
gaining popularity. Bardy et al demonstrated that a biphasic shock of 130J was equivalent 
to a monophasic damped sinusoidal shock of 200J with both achieving an efficacy of 
86%. (55) In animals biphasic shocks have been shown to cause less left ventricular 
dysfunction following resuscitation from ventricular fibrillation. (56) This may prove to be 
clinically relevant When performing elective cardioversion of atrial fibrillation in patients 
with cardiomyopathy. At present most defibrillators used in hospital practice deliver 
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monophasic damped sinusoidal waveform. shocks this is however likely to change as newer 
models are introduced. 
There has been great debate as to the appropriate energy level when attempting to 
cardiovert atrial fibrillation. Ricard et al compared the minimum energy required to 
cardiovert nearly 200 patients with chronic atrial fibrillation. (5 7) They found that nearly 
half of the patients successfully cardioverted with shocks of less than or equal to I OOJ with 
75% cardioverting with up to 200J. They recommended a protocol with a starting energy 
of 50J. Joglar et al used a different method to compare initial energy settings. (58) Instead 
of using a step up protocol patients were randomised to receive I OOJ, 200J or 360J as the 
initial shock. They showed that a much lower success rate was achieved when I OOJ or 200J 
were used initially as compared to 360J. Troponin I samples were studied to show that a 
high initial energy level did not cause cardiac darnage. They concluded that an energy level 
of 360J might be the most appropriate starting point. Most protocols used in clinical 
practice are of the "step up" variety. Using this method the energy level is increased after 
each failed attempt until either a maximum energy is reached or a maximum number of 
shocks have been delivered. 
1.12.2.1 Complications of external electrical cardioversion 
Although elective DC cardioversion of atrial fibrillation is a relatively safe 
procedure it is not without risk. The most commonly encountered complication is 
thromboembolism following restoration of sinus rhythm. Other complications include 
transient bradycardia, ventricular arrhythmias, hypertension, pulmonary oedema and 
transient ST segment elevation. 
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1.12.2.2 Thromboembolism and cardioversion 
Both electrical and chemical cardioversion of atrial fibrillation are associated with 
an increased risk of thromboembolic episodes. (5 9-6 1) The postulated mechanism for this 
complication is that preformed intra. cardiac thrombi are ejected from the atria or atrial 
appendage when atrial contraction is restored. The discovery that atrial contraction may 
not return to normal immediately following cardioversion explains why the peak incidence 
of thromboembolism occurs three days post procedure. In order to try and reduce this risk 
the American Association of Chest Physicians recommends that patients should receive 
anticoagulation for at least 3 weeks prior to cardioversion and 4 weeks post successful 
cardioversion. (62) This does not however completely eliminate the increased risk of 
thromboembolic complications following cardioversion. (61,63) Bjerelund and Orning 
studied 437 patients assigned to either receive anticoagulation or placebo prior to 
cardioversion. They found a 0.8% incidence of clinically apparent thromboemboli in the 
anticoagulated group compared to 5.3% in those without prior anticoagulation. (61) 
Another means of decreasing the risk of thromboembolic complications associated 
with cardioversion centres on the use of transoesophageal echocardiogmphy (TOE). 
Transoesophageal echocardiography allows the atria and atrial appendages to be inspected 
in detail. This allows the visualisation of pre existing intra atrial thrombus, which is 
thought to predispose to thromboembolic complications. The accuracy of this method for 
thrombus exclusion has recently been studied by Fatkin et al. (64) They performed 
transoesophageal echocardiography in 60 patients undergoing cardiac surgery and 
compared the accuracy of TOE diagnosis with intraoperative detection of thrombus. They 
concluded that TOE had a high sensitivity and specificity but a low positive predictive 
value. This data has led some groups to advocate the use of TOE to screen patients with 
chronic atrial fibrillation with a view to proceeding immediately to cardioversion without 
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prior anticoagulation in those patients without evidence of thrombus. Stoddard et al studied 
206 patients and proceeded to cardioversion in 153 in whom atrial thrombus had been 
excluded by TOE. (65) They reported no thromboembolic complications after a4 week 
follow up period. Klein et al used a different strategy allocating patients to conventional 
anticoagulation or short term anticoagulation prior to cardioversion. (66) Those patients in 
the short term group were prescribed warfarin and a TOE and cardioversion performed as 
soon as a stable INR was achieved. Anticoagulation was continued for at least four weeks 
following successful cardioversion . No significant difference in the incidence of 
thromboembolic complications was found between the two groups. 
Despite these results it should be remembered that the absence of thrombus on 
TOE does not eliminate the risk of thromboembolism. In 17 patients who had 
thromboembolic complications post cardioversion, Black et al found that a 
precardioversion TOE had shown spontaneous contrast in 5 patients but no evidence of 
formed thrombus in any. (67). They concluded that these thromboembolic episodes were 
either as a result of a false negative TOE examination or de novo thrombus formation post 
cardioversion. 
At North Tyneside General Hospital we use a hybrid of these strategies in an 
attempt to achieve the lowest risk of thromboembolic complications possible. Patients are 
anticoagulated with warfarin for four weeks in the conventional manner and then proceed 
to transoesophageal echocardiograrn prior to cardioversion. Patients with no evidence of 
intracardiac thrombus proceed immediately to DC cardioversion. If intra cardiac thrombus 
is seen DC cardioversion is postponed and warfarin therapy continued for a further six 
weeks. A repeat TOE is then perfonned. If this second TOE proves negative then DC 
cardioversion is attempted. 
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1.12.3 Internal electrical cardioversion 
Internal electrical cardioversion is a new technique involving the insertion of an 
intracardiac catheter and the delivery of low energy shocks, typically 2 to 6 joules, direct to 
the myocardium in an attempt to produce sinus rhythm. This technique may be particularly 
useful in patients whose atrial fibrillation is unresponsive to external cardioversion. In a 
study by Schmitt et al 25 patients who had failed to respond to external cardioversion 
underwent internal cardioversion. Successful restoration of sinus rhythm was achieved in 
88% of patients. Since this approach involves the insertion of an intracardiac catheter it 
carries the potential complications including cardiac puncture, bleeding and infection. The 
facilities required to carry out internal cardioversion currently limits its use to major 
centres. 
1.13 Invasive treatments 
A more invasive approach may be required for symptomatic patients if rate and 
rhythm control has proved impossible using the approaches outlined. Several options are 
available. 
1.13.1 AV node ablation and ventricular pacing 
Atrioventricular node ablation with ventricular pacing was originally described by 
Scheimnan in 1982. (68) A high-energy radiofrequency current is used to destroy the 
atrioventricular node and produce complete heart block. A pacemaker is inserted to 
maintain an adequate ventricular rate. Thus control of the ventricular rate is achieved at the 
expense of loss of normal physiological regulation and atrial transport. If single lead 
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ventricular pacing is employed the thromboembolic risk due to decreased atrial contraction 
remains. Patients should therefore be maintained on warfarin therapy for thromboembolic 
prophylaxis. 
1.13.2 Focal ablation 
Focal ablation is most often used in younger patients who have paroxysmal 
episodes of atrial fibrillation. The technique relies on the isolation one or more trigger foci 
responsible for initiating the arrhythmia. These foci usually lie either in the pulmonary 
veins or less commonly in the right atrium. Following their identification radiofrequency 
ablation is applied to the area surrounding each focus in order to isolate it from the rest of 
the myocardium. Thus preventing the propagation of the fibrillatory potentials. 
1.13.3 The surgical maze procedure 
The maze procedure, first performed in 1987 by Cox, involves the surgical excision 
of the atrial appendages and the isolation of the pulmonary veins. (69) Incisions are also 
made within the atria so as to form a "corridor" of atrial tissue from the sinus node to the 
atrioventricular node. Further incisions ensure that the atrial tissue is divided into strips too 
narrow to allow atrial fibrillation to occur. One of the major limitations of the procedure is 
that cardiopulmonary bypass is required. The maze procedure can however be carried out 
in conjunction with other cardiac surgery. Sandoval et al reported a series in which the 
maze procedure was carried out at the time of mitral valve replacement. (70) They reported 
restoration of sinus rhythm in 85% of patients undergoing the combined procedure with an 
operative mortality of 5%. Of those patients achieving sinus rhythm evidence of atrial 
contraction was present in around two-thirds with the remainder requiring continued 
anticoagulation. Raanani et al reported similar results. They compared forty seven patients 
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with atrial fibrillation undergoing mitral. valve surgery and the maze procedure with forty 
seven matched subjects who underwent mitral valve surgery alone. Operative mortality 
was similar in both groups but sinus rhythm was maintained in 75% of the maze group 
compared with 36% in the non maze group (P=0.0004). After three years of follow up 
none of the maze group had suffered a thromboembolic complication as compared to 15% 
of the non maze group (P=0.03). (7 1) 
A minimally invasive variation of the maze procedure has recently been reported 
by Lee et al. (72) They performed the maze procedure via a tunnelled approach in 10 dogs 
with artificially induced atrial fibrillation. Cardiopulmonary bypass was not required 
during any of the procedures and sinus rhythm was restored in all 10 animals with no 
operative deaths. No data for this procedure in humans currently exists. 
1.13.4 The catheter maze procedure 
A further modification of the maze procedure has been developed using 
radiofrequency ablation catheters to create the corridors necessary to prevent atrial 
fibrillation. (73) These linear scars appear to give success rates for maintaining sinus 
rhythm in the region of 40 to 50%. The relatively low success rate coupled with a high 
incidence of complications has lead electrophysiologists to look for alternative approaches. 
Initially areas of automaticity within the pulmonary veins themselves were targeted in an 
individual manner in an attempt to abolish foci responsible for initiating atrial fibrillation. 
Using this approach success rates rose to around 65% however multiple procedures were 
often necessary. The realisation that initiating foci could be present not only in the 
pulmonary veins but in many different areas of the atria lead to the development of more 
anatomically based techniques. Applying a technique of circurnferentially isolating the 
pulmonary vein ostia, from the atrium has produced success rates for maintaining sinus 
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rhythm in the order of 70% without the need for continuing antiarrhythmic medication. 
This anatomical approach was also used by Pappone et al who used a non fluoroscopic 
mapping system and radiofrequency ablation delivered circurnferentially outside the ostia 
of the pulmonary veins to electrically isolate potential triggers for atrial fibrillation. In a 
series of 26 patients 85% were AF free with 62%taking no antiarrhythmic medication at 
follow up. (3) 
Although catheter ablation for atrial fibrillation shows promise for the future it 
currently limited to highly selected cases in part due to the need for often lengthy 
procedures. It is hoped however that further refining both the equipment and the techniques 
used may lead to ablation of atrial fibrillation being more widely available. 
1.13.5 Pacing techniques 
Atrial pacing has been suggested as a means of both treating and preventing 
paroxysmal atrial fibrillation. Levy et al investigated the potential of biatrial. pacing, right 
atrial pacing and no pacing in preventing episodes of paroxysmal atrial fibrillation in 
patients refractory to anti arrhythmic medication. (74) They found that both biatrial and 
right atrial pacing decreased episodes in comparison to no pacing. No significant 
difference in episodes was noted between the two pacing methods. 
1.13.6 Implantable atrial defibrillator 
The implantable atrial. defibrillator has been used in highly symptomatic patients 
who are unable to tolerate other therapy. Early defibrillators required activation by a 
physician but newer models allow the patient to activate the device. This removes the 
potential for unexpected painftil shocks and allows patients who prefer to have sedation for 
the procedure to enlist medical help. (75) Although promising results have been seen the 
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use of the atrial defibrillator devices is likely to remain limited in part due to the high cost 
of the units used. 
1.14 Relapse Rates Following Cardioversion 
The safety, wide availability and high initial success rate of external DC 
cardioversion makes it an attractive proposition for the treatment of chronic non valvular 
atrial fibrillation. The long-tenn result of a successful procedure is that the patient is 
returned to sinus rhythm with a theoretical reduction for all the complications outlined 
above including mortality. The patient should not be required to take medication long term 
as is the case with the strategy of rate control and anticoagulation. Restoration of sinus 
rhythm occurs in a controlled manner with electrical cardioversion unlike pharmacological 
cardioversion where sinus rhythm may return at any time throughout the treatment period. 
Electrical cardioversion has also been shown to be the most cost effective treatment 
when compared to rate control and thromboernbolic prophylaxis. Catherwood et al used a 
decision analytical model to estimate the costs associated with different treatment 
strategies for chronic non valvular atrial fibrillation. (76) They compared DC cardioversion. 
alone, rate control plus long-tenn anticoagulation and pharmacological cardioversion of 
patients presenting with newly diagnosed chronic non valvular atrial fibrillation. Electrical 
cardioversion was the most cost effective strategy costing $1920 per quality adjusted life 
year (QALY) compared to figures for rate control and warfarin of $2091/QALY. Rate 
control in combination with aspirin although cheaper initially incurs greater cost due to late 
complications such as stroke and is therefore less cost effective in the long term incurring 
costs of $2380/QALY. 
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The major limitation of DC cardioversion is the high incidence of relapse to atrial 
fibrillation following an initially successful procedure. The relapse rate is highest within 
the first month with rates as high as 30% being reported. (77) Relapses continue to occur 
with time and relapse rates at one year typically range between 45 and 70%. 
Antiarrhythmic prophylaxis following successful cardioversion has been used to attempt to 
decrease this rate of relapse to atrial fibrillation. With antiarrhythmic prophylaxis relapse 
rates fall depending on the drug used. Relapse rates are reduced with quinidine therapy at 
the expense of an increase in mortality making quinidine an unattractive agent for routine 
use. Flecanide and propafanone have also been shown to reduce relapse rates but their use 
in patients with reduced left ventricular function and ischaernic heart disease is limited as 
previously described. 
Despite a paucity of controlled trials amiodarone is thought to be the most 
successful agent at maintaining sinus rhythm with reported relapse rates varying from 17% 
to 64% at one year depending on patient selection. (78) Arniodarone is however associated 
with a wide variety of side effects making routine long term prophylaxis less attractive to 
young patients or those with few symptoms. 
1.15 Prediction of relapse 
The ability to predict which patients will relapse to atrial fibrillation has obvious 
advantages depending on when prediction is possible. If patients who are likely to relapse 
to atrial fibrillation can be reliably identified prior to undergoing DC cardioversion 
targeting of the procedure becomes a feasible proposition. This would allow those patients 
who have little or no chance of maintaining sinus rhythm to avoid the risks of the 
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procedure. This would also have resource implications allowing efficient use of both 
cardioversion facilities and physician time. 
However if prediction of relapse is only possible after cardioversion has been 
carried out, targeting of antiarrhythmic medication is the most realistic goal. Since all 
antiarrhythmic agents currently available have potentially serious side effects limiting their 
use to those who definitely require them would appear desirable. This would allow patients 
who are unlikely to relapse to avoid potentially lethal side effects. The identification of 
patients who have a high chance of relapse would also provide an ideal group of patients in 
which to evaluate future treatment strategies such as new antiarrhythmic drugs. 
Many different variables have been evaluated in an attempt either to limit the use of 
cardioversion to those in whom long-term success can be achieved or to predict relapse. To 
date no reliable method of predicting relapse following successful cardioversion has been 
identified. 
1.15.1 Patient age and relapse 
Atrial. fibrillation becomes more common with advancing age and it is in older 
patients that the rate of complications is highest. The risk of thromboembolism is 
especially important in elderly patients and has lead to recommendations that older patients 
should be targeted for prophylaxis. Thus maintenance of sinus rhythm where possible is 
especially beneficial in older subjects. Whether age is an independent predictor of success 
of DC cardioversion is still unclear. In a study of patients with chronic atrial arrhythmias, 
Van Gelder et al appeared to show that advancing age was associated with a decrease in 
initial success and an increased rate of relapse. (79) However this study included patients 
with both atrial fibrillation and atrial flutter. No such relationship was found by Carlsson et 
al (80) who compared 582 patients aged 65 and over undergoing cardioversion with 570 
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patients under 65 undergoing the same procedure. Success rates and complication rates 
were similar in both groups. 
On current evidence age would not appear to be a particularly useful predictor of 
either initial success or relapse to atrial fibrillation. 
1.15.2 Duration of arrhythmia and relapse 
Several authors have shown that arrhythmia duration is a strong predictor of failure 
of maintenance of sinus rhythm following cardioversion. (79,81-85) In particular atrial 
fibrillation ot'short duration related to a correctable cause is least likely to recur. 
Duytschaever et al used multivariate analysis to identify factors predicting relapse in 85 
patients 1*61lowing successful card i oversi on. (96) Duration of arrhvtliiiiia was t`6und to be 
the most reliable predictor of relapse. Van den Berg et al also showed how an increasing 
duration ot'arrhythnila was associated with a failure to achieve sinus rhythm at 
cardioversion (see table 4). (87) 
Duration of atrial fibrillation Increase in risk of failure to 
cardiovert 
<3 months 0 
3- 36 months 4 1`61d increase 
> 36 months 23 fold increase 
Table 4 F, stu-nated risk of failure to cardiovert by duration of atnal fibrillation 
Fhese findings have lead the Royal College of'physicians of Edinburgh to 
recommend DC cardioversion only for patients with atrial fibrillation ofless than 3 months 
duration or patients with arrhythrma duration greater than three months accompanied by 
symptoms. (47) The major limitation with this strategy is the difficulty in precisely 
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determining the onset of atrial fibrillation. Thus cardioversion is currently frequently 
offered to patients with a duration of atrial fibrillation in excess of three months. Further 
work on the role of arrhythmia duration is clearly required. 
1.15.3 Functional class, co morbidity and relapse 
Although several conditions have been shown to predispose to the initiation of 
atrial fibrillation data regarding the influence of co-morbidity on relapse following 
cardioversion is lacking. This is in part because patients with extensive co-morbidity are 
often excluded from studies that aim to identify factors responsible for relapse. The 
presence of rheumatic heart disease has however been shown to lower both initial and long 
term success of DC cardioversion. (82) 
Pre cardioversion functional class is one factor that may be useful when predicting 
relapse. Van Gelder et al showed that patients with symptomatic ventricular dysfunction, 
defined as New York Heart Association class III or IV, had a significantly higher rate of 
relapse compared to matched individuals with no symptoms of ventricular dysfunction. (79) 
At present the major reason for assessing comorbidity and functional class is to identify 
those patients in whom cardioversion is contraindicated. It is not used routinely to predict 
relapse. 
1.15.4 Transthoracic echocardiography and relapse 
It is conventially thought that an enlarged left atrial diameter is associated with an 
increased risk of initial failure of cardioversion or tendency to relapse to atrial fibrillation. 
The evidence to support this assumption is however less than conclusive. In the two 
previously mentioned studies by Van Gelder and Duytschaever no association between left 
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atrial size and successful cardioversion was demonstrated despite a total of over 300 
patients being involved. On the other hand Brodsky et al studied 43 patients who all had 
symptomatic atrial fibrillation and dilatation of the left atrium (LA size 45 to 78mm). They 
found that LA size greater than 60mm was associated with an increased risk of relapse 
within the six month follow up period. Gross atrial enlargement may prove to be a useful 
predictor of relapse even though moderate enlargement appears to be less predictive. 
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1.15.5 Transoesophageal echocardiography and relapse 
Recently interest has increased in the use transoesophageal echocardiographic 
measurements in the prediction of relapse to atrial fibrillation. Verhorst et al carried out 
TOE assessment of 62 patients prior to cardioversion for chronic atrial fibrillation. (88) 
Patients who underwent successful cardioversion were followed up for one year and 
subsequently divided into two groups. Group one remained in sinus rhythm for the entire 
follow up period, the second group comprised patients who relapsed to atrial fibrillation. A 
longer duration of atrial fibrillation, larger LA or annulus dimensions, the presence of 
spontaneous echo contrast and reduced appendage flow were all found to be associated 
with a return to atrial fibrillation. Manabe et al looked at left atrial appendage (LAA) flow 
as a predictor of successful cardioversion. (89)- They concluded that LAA flow velocity of 
greater than 19cm/sec was both sensitive (80%) and specific (88%) as a predictor for 
successful cardioversion. However Perez et al were unable to show the same relationship 
for any echocardiographic parameter showing only that LAA flow velocity was related to 
left ventricular function. (90) 
Each of these studies involved relatively small numbers of highly selected patients 
making extrapolation of this data to everyday clinical practice difficult. At North Tyneside 
General Hospital all patients have a TOE to exclude left atrial appendage thrombus prior to 
DC cardioversion. These patients provide an ideal opportunity to gain valuable information 
as to the role of transoesophageal echocardiographic measurements in the prediction of 
relapse of atrial, fibrillation following DC cardioversion in everyday UK practice. 
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1.15.6 Signal Averaged ECG and relapse 
The signal-averaged electrocardiogram (SAECG) has been extensively 
investigated over the last 20 years. Ever since Simson detected late potentials in the QRS 
complex in 1981 interest has centred on signal averaging techniques and ventricular 
arrhythmias. (9 1) Here late potentials are thought to represent delayed cardiac activation 
providing a substrate for re-entry and initiating ventricular arrhythmias. (92-94) 
More recently interest has increased on the possibility of using signal averaging 
techniques to study atrial fibrillation. (95-97) Mechanisms similar to those outlined above 
are thought to be involved in the propagation of atrial arrhythmias. The atria are believed 
to contain areas of slow conduction allowing a re-entrant mechanism to exist. (1,97,98) 
These areas of slow conduction are thought to give rise to late potentials detectable within 
the p wave on signal averaging in the same way as ventricular late potentials are visible 
within the QRS complex. There is still however great debate as to the role of signal 
averaging techniques in atrial fibrillation. 
1.15.6.1 The evidence for a relationship between signal averaging 
and atrial fibrillation 
Guidera et al studied 15 patients with paroxysmal atrial fibrillation and compared 
both their 12 lead and signal averaged ECG with those of 15 age and sex matched control 
subjects. (I 18) They found no difference in p wave duration on standard 12 lead ECG, 
however mean unfiltered and filtered p wave duration was significantly lengthened in those 
patients with atrial fibrillation. A study of 51 patient with atrial fibrillation following 
coronary artery bypass grafting showed similar results with no significant difference in p 
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wave duration on standard 12 lead ECG and an increased signal averaged p wave duration 
compared to control subjects. (I 19) Further evidence for an association between signal 
averaged parameters and atrial fibrillation was provided by Villani et al. (120) In a study of 
40 patients (20 with atrial fibrillation) they found that an increase in p wave dispersion and 
the p wave dispersion index (p wave dispersion index = {p duration (X, Y, Z, leads) S. D. / 
mean value )x 100 ) were significantly associated with episodes of atrial fibrillation. 
There was no significant difference in root mean square voltage of the last 20 milliseconds 
of the p wavc (RMS20). 
Several groups have considered the use of P wave signal averaging to predict the 
relapse to atrial fibrillation following initially successftil DC cardioversion. Opolski et al. 
recorded signal averaged ECG in 35 patients following DC cardioversion and found that 
the II patients who relapsed into atrial fibrillation had a significantly longer p wave 
duration(I 2 1). Stafford et al produced similar data in patients who had relapsed following 
internal cardioversion. (1 19) One of the largest published series is that of Aytemir et al who 
measured p wave signal averaged ECG in 73 patients following cardioversion. (122) They 
also found significant differences in p wave duration with patients who relapsed showing 
longer p wave duration. 
1.15.6.2 The evidence against a relationship between signal averaging 
and atrial fibrillation 
Despite the positive results outlined above there is still some debate about the 
association between signal averaged p wave duration and atrial fibrillation with several 
groups unable to show a relationship. Frost et al looked at p wave duration and 
morphology of 189 patients undergoing coronary artery bypass grafting of which 42 
developed atrial fibrillation. (123) No significant relationship was found between p wave 
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duration or morphology and the likelihood of an episode of atrial fibrillation. Turrito et al 
used several variables including p wave duration to attempt to risk stratify patients with 
regard to atrial tachyarrhythmias. . (124) Only left atrial AP diameter was found to be a 
useful predictor of arrhyflunia recurrence. 
1.15.6.3 Possible causes of conflicting results 
Both the lack of standardisation and problems with reproducibility of the p wave 
signal averaged ECG have been proposed as possible causes for the different outcomes in 
the above studies. The technique has, however, been shown to have a high degree of short 
and medium term reproducibility. (125) Another suggested reason for these conflicting 
outcomes is the filtering method used. Signal averaged signals can be filtered, prior to 
analysis, by a number of different methods including unidirectional, bi-directional, finite 
impulse response, least-squares fit and spectral (Fourier) filters. Ehlert et at studied these 
different filtering processes and concluded that least-squares fit filtering with a bandwidth 
of 29-250 Hz and QRS triggering provided the most reliable results. (126) 
A further discrepancy between the various studies would appear to be the 
antidysrhythmic medication at the time of inclusion. It has been shown that class I and 
class III agents change the characteristics of the p wave signal averaged ECG. However in 
many of the studies these medications were used in some or all of the patients enrolled. 
This may help to explain the inconsistency of the results obtained. (I 11,127-129) 
1.15.7 Heart rate variability 
Although the precise electrophysiology of atrial fibrillation remains largely unclear 
it has been recognised for some time that changes in the autonomic nervous system play an 
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important part in initiation of atrial fibrillation. Heart rate variability measurements have 
been proposed as a means of none invasively measuring autonomic activity. 
The term heart rate variability has become the accepted term for the natural 
variation of the cardiac rate and RR intervals. Other tenns, which have been used 
previously, include cycle length variability, heart period variability and RR variability. 
One of the major limitations of heart rate variability measurements to date has been 
the lack of standardisation of both measurements and nomenclature. Despite these early 
difficulties it has been suggested that the measurement of heart rate variability can be used 
to obtain an accurate non-invasive marker of autonomic modulation. (99) In an attempt to 
solve this problem a special report from the Task Force of the European Society of 
Cardiology and the North American Society of Pacing and Electrophysiology was 
published in 1996. They attempted to set minimum standards for measuring heart rate 
variability and guidelines for the interpretation of results. (100) 
Heart rate variability measurements can be divided into two groups, time domain 
and frequency domain measurements. Both types of analysis are made from measurements 
taken from adjacent cardiac beats in a continuous electrocardiogram recording. 
1.15.7.1 Time domain analysis 
Time domain analysis provides information on the amount of variation around the 
mean heart rate. There are two main classes of time domain variables, the first relating to 
the variation in cycle length throughout the given time period and the second giving a 
measure of variation in the length of adjacent cycles. The most commonly used variables 
in the first group are SDNN and the SDANN. These measurements of interbeat variation 
are influenced by both short tenn (respiration) and long term (circadian) factors. 
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'rhe second class ot'variable includes pNN50 and RMSSI). Tlicsc variables arc 
not thought to be affected by long term trends and represent a measure ot'vagal tone (see 
table below). (] 0 1) 
Variable Units Definition 
Standard deviation of all normal RR intervals in the 
SDNN ms 24 hour recording. 
Standard deviation of the mean ofall 5 minute 
SDANN ms segments of normal RR intervals of a 24 hour 
recording. 
Mean of the standard deviations ofall NN intervals 
S[)NNi ms for all 5 minute segments ofa 24 hour recording 
Number ol'pairs of ad 
. jaccrit 
NN interv ils differing 
SNN50 11 by greater than 50ms per 24 hours standardised flor 
inc/dec/total invalid intervals 
Number of pairs of adjacent NN intervals differing 
SNN6% n by greater than 6% per 24 hours standardised for 
invalid intervals 
Percentage of RR intervals between aqjacent 
pNN50 % normal RR intervals that are greater than 50 msec 
computed over the entire 24 hour ECG recording. 
Root mean square ot'successive differences, the 
RMSSI) msec square root ofthe mean of the sum of the squares of 
the differences between adjacent RR intervals over 
the entire 24 hour recording 
Table 5 Definitions ofthne domain heart rate variability measurements. 
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1.15.7.2 Frequency Domain Analysis 
Frequency domain analysis provides information on the periodic oscillation ofthe 
heart rate at various frequencies. Three main spectral components are calculated using 
frequency domain analysis from short-term recordings ofheart rate. They are very low 
frequency (VIT). low frequency (1, F), and high frequency (HF) components(100,102,103) 
HF and LF power is not constant but varies with varying autonomic tone. The precise 
determinants of each spectral frequency band is not yet fully established but it is thought 
that vagal activity is the major factor in determining I IF power. Some authors have 
suggested that the LF component ot'heart rate variability gives a measure o I'sy in pathetic 
activity whilst others state that it is influenced by both sympathetic and vagal activity. The 
physiologleal significance ofVl, F is even less well defined and further work is required to 
determine its significance. 
Variable Units Description Frequency Range 
V1,11, rns 2 Power in VIT, range <=0.04 11z 
1A., ms 
2 Power in LF range 0.04 - 0.15 liz 
IIF ms 2 Power in III, ' range 0.15 - 0.4 Ilz 
Table 6 Definitions of frequency domain heart rate variability measurements 
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1.15.7.3 Duration of ECG Recording 
Analysis can be performed on both short and long term recordings. (100) The 
commonest recording to be subjected to analysis is the 24 hour ambulatory recording. This 
long-term recording is useful when studying heart rate variability at different times within 
the same patient or in-patients who are limited in their activities. However the fact that 
heart rate variability is influenced by physical activity makes this analysis difficult, if not 
impossible, to interpret on outpatients due to problems of standardisation. 
Short-term measures of heart rate variability have the advantage of allowing 
standardisation of conditions. This means that recordings can be more easily compared 
between individuals and groups of individuals. To achieve these standard conditions care 
must be taken to record the measurement at the same time of day, ambient temperature, 
and position, in an environment free from exogenous stimuli and at the same respiratory 
rate. It has been suggested that 5 minute recordings should be used and that more than one 
5 minute period should be measured to ensure stationarity. 
In general, time domain analysis is preferred when studying long term 
measurement and frequency domain analysis preferred for short-terrn measurements. 
1.15.7.4 Time and Amplitude Resolution 
Since accuracy of recognition is governed by the sampling frequency it is crucial 
to select the correct frequency in order to obtain accurate measurement of the RR interval. 
It has been suggested that this should be at least in the range 250 - 500 Hz or if possible 
higher. (102) The amplitude resolution of the analogue to digital conversion should be 
sufficiently large as to allow accurate point resolution of the signal. (100) 
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1.15.7.5 Editing 
Accurate editing is required prior to either time or frequency domain analysis. 
Ectopic beats must be removed and only "normal" RR intervals used in analysis. One 
method of ensuring that only normal RR intervals are included is to exclude all those RR 
intervals which differ by greater than 20% from the preceding RR interval. This can be 
done automatically but can lead to greater errors as a proportion of normal RR intervals 
will be eliminated. (104-106) In a study of interobserver reproducibility Kroll et al showed 
that manual editing gave high levels of reproducibility for both time and frequency 
analysis. (107) 
1.16 Clinical Applications of Heart Rate Variability 
1.16.1 Atrial Fibrillation 
At the time of writing no data exists with regard to the use of heart rate variability 
following DC cardioversion of chronic atrial fibrillation. 
Fioranelli et al. calculated heart rate variability in 28 patients, with no evidence of 
heart disease, in whom a period of paroxysmal atrial. fibrillation (PAF) was reported on a 
24 hour ECG. (I 08) They compared a period 5 minutes prior to AF with a period at least 
one hour after the tennination of AF. They concluded that the episodes could be divided 
into two types. In type A episode they found an increase in LF and a decrease in HF power. 
In type B they found an increase in HF power and a decrease in LF power. They concluded 
that type A episodes were associated with an increase in sympathetic drive and type B 
episodes with an increase in parasympathetic drive. These conclusions fail to take into 
account that although it is generally agreed that HF power is a marker of vagal activity, 
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there is still disagreement as to the exact relevance of LF power. It has been suggested by 
some authors that LF power represents both sympathetic and vagal components of heart 
rate variability. 
Herweg et al. measured heart rate variability in 29 patients with PAF and concluded 
that HF power changes were also present before most episodes of AF but that circadian 
differences were present. Increased parasympathetic activity preceded mostly nocturnal AF 
and this tended to occur in younger patients. Daytime episodes were preceded by a 
decrease in parasympathetic activity as seen by a decrease in HF power. (I 03) 
Studies of heart rate variability after coronary artery bypass grafting have shown a 
decrease in the low frequency / high frequency ratio prior to initiation of atrial fibrillation 
leading to the conclusion that AF may be a result of loss of vagal tone. (I 09)- Hogue et al 
used approximate entropy (ApEn) analysis to study ECG recordings from 18 patients who 
developed paroxysmal atrial fibrillation following coronary artery bypass surgery. These 
episodes, 24 in all, were compared to age and sex matched controls who had also 
undergone surgery. They concluded that increased heart rate and decreased ApEn was 
associated with PAF post surgery and may prove to be a useful predictive marker. (I 10) 
1.16.2 Myocardial Infarction 
Depressed heart rate variability after myocardial infarction is associated with an 
increase in mortality, particularly arrhythmic events. (108,109,1 11) This decreased 
variability was detected as a decrease in HF power and an increase in LF power. This may 
represent a loss of parasympathetic control with a shift of balance towards sympathetic 
drive. This helps to explain some of the benefits seen with beta blockers, post myocardial 
infarction. Beta blockers have been shown to prevent the rise in LF power seen during 
moming hours and decrease mortality. (I 12)78 
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1.16.3 Congestive Cardiac Failure 
Patients with congestive cardiac failure show large reductions in both HF and LF 
power with little difference in the HF/LF ratio. (I 13-115) These changes are associated 
with a dramatic reduction of life expectancy. Whether this is a causal relationship has yet 
to be determined. 
1.16.4 Diabetic Neuropathy 
In diabetic patients a reduction in the time domain measurements of heart rate 
variability has been shown to be associated with a poor prognosis. There is evidence that 
the decrease in heart rate variability predates the clinical expression of diabetic neuropathy. 
This raises the possibility of using heart rate variability measurements to identify those 
patients most at risk of developing neuropathy and allow preventative treatment to be 
implemented early. (I 16,117) 
1.16.5 Heart Rate Variability Following DC Cardioversion 
Heart rate variability has been shown to be a useful tool in the prediction of 
ventricular arrhythmias following myocardial infarction. Evidence exists that measurement 
of heart rate variability may give useful information with regard to atrial fibrillation 
following coronary artery bypass grafting, however, the use of heart rate variability in 
predicting the long-term success of DC cardioversion has not been studied. This may prove 
to be an easily performed non-invasive means of predicting long term outcome, thus 
allowing targeted antiarrhythmic prophylaxis. Further work is required to define the role of 
heart rate variability measurement in predicting long term outcome of DC cardioversion. 
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1.17 Summary 
Atrial fibrillation is the commonest sustained cardiac arrhythmia and is associated 
with substantial morbidity and mortality. External DC cardioversion is a reliable means of 
restoring sinus rhythm in the majority of patients its usefulness is however limited by a 
high rate of relapse. These relapse rates can be decreased by the use of antiarrhythmic 
prophylaxis at the expense of potentially life threatening side effects. The ability to predict 
which patients will relapse following cardioversion may allow targeting of prophylactic 
antiarrhythmic therapy. It is clear that further work is required to identify whether 
prediction of relapse is possible and if so which factors are most helpful in everyday 
practice. The following research project was carried out in an attempt to clarify whether 
transoesophageal. echocardiography, p wave signal averaging and heart rate variability had 
a part to play in identifying relapse following DC cardioversion. 
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2 Methods 
2.1 Study Aims 
The main aim of this study is to assess to what extent measurements from 
transoesophageal echocardiography, P wave signal averaged electrocardiography and heart 
rate variability can be used to predict a successftil long term outcome in patients 
undergoing DC cardioversion for atrial fibrillation. 
2.2 Study Design 
A prospective observational study design was employed. The study was carried out 
wholly at North Tyneside General Hospital. Ethical approval was obtained from the Joint 
Ethics Committee of Newcastle and North Tyneside Health Authority. 
2.3 Statistical Power 
The number of patients required to achieve a meaningful result was estimated by 
means of a power calculation. Ap value of less than 0.05 was taken to represent a 
statistically significant result. Several assumptions were made in order to carry out the 
calculation. The first of these assumptions was that ten percent of those initially enrolled 
would fail to make it to DC cardioversion. This would include patients who spontaneously 
reverted to sinus rhythm or were found to have a treatable cause for their atrial fibrillation, 
patients who were unable to tolerate the TOE procedure, those who were found to have a 
clot at TOE and those who failed to attend for the follow up appointments. It was assumed 
that of those patients who proceeded to DC cardioversion approximately 80% would 
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initially cardiovert to sinus rhythm and of those achieving sinus rhythm approximately 
50% would relapse to atrial fibrillation during the study period. When considering the 
signal averaged ECG parameters it was decided that a difference in p wave duration of 10 
milliseconds could be reliably detected and would be clinically useful. Using these 
assumptions it was calculated that a minimum of seventy patients would be required to 
undergo DC cardioversion to give a meaningful result. Allowing for the previously 
mentioned drop out rate this meant that a minimum of around 77 patients would need to be 
recruited. When similar calculations were performed using TOE variables and heart rate 
variability variables it was found that lower numbers of patients were thought to be 
required to provide a meaningful result for these variables. Given that the power 
calculation had suggested that at least 77 patients would be required a recruitment goal of 
100 patients was set. 
2.4 Patient Recruitment 
Patient recruitment was limited to the North Tyneside General Hospital catchment 
area. All patients were referred either from a hospital physician or family practitioner to 
the cardiology services at North Tyneside General Hospital with a diagnosis of atrial 
fibrillation. The inclusion and exclusion criteria set out below were used to screen referrals 
prior to patients being invited to take part in the study. 
Inclusion criteria 
1. Atrial fibrillation present for greater than 48 hours. 
Age greater than 18 years of age. 
3. No physical or echocardiographic evidence of valvular heart disease. 
4. No contraindications to warfarin therapy. 
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5. No contraindications to DC cardioversion. 
6. No contraindications to general anaesthesia. 
Exclusion criteria 
1. Oesophageal disease or contraindication to transoesophageal echocardiography 
2. Patients taking either class I or class III antiarrhythmic medication. 
3. Patients with acute coronary syndromes. 
4. Uncompensated heart failure. Defined as NYHA class IV. ' 
5. Inability to give infonned consent. 
6. Pregnancy. 
Patients who were taking class I or class III antiarrhythmic medication were 
excluded as both these groups of drugs effect P wave morphology. This would lead to 
problems interpreting P wave signal averaging measurements. Patients previously taking 
such medication who had not taken the drug for a period equal to or greater than five times 
its half-lifc werc cligiblc for inclusion. 
2.5 Initial Assessment 
Following referral those patients who met the criteria outlined above were invited 
to attend the outpatient department. All patients were given information with regard to the 
diagnosis of atrial fibrillation and the possible treatment options available. An information 
leaflet was provided (see appendix 1) that explained the nature of the study and what was 
involved should they wish to participate. All patients were asked to sign a consent form to 
indicate whether they would like to take part in the study (see appendix 2). 
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At the initial assessment visit all patients underwent a full physical examination to 
ensure suitability for inclusion. The following additional data was collected. 
1. Demographic data: Patient age, sex. 
2. Clinical data: Duration of atrial fibrillation, previous ischaemic heart disease, 
hypertension, stroke, alcohol consumption and previous arrhythmias. 
3. Biochemical data: Urea and electrolytes, thyroid function tests 
4. Standard 12 lead electrocardiogram. 
For the purposes of this study the duration of atrial. fibrillation was taken to be the 
longest of either the time from first diagnosis or the time from which the patient first 
noticed the presenting symptom to the date cardioversion was attempted. 
All data was held on a Microsoft Access computer database. 
2.6 Anticoagulation 
All patients who consented to take part in the study were anticoagulated following 
the guidelines set out by the American College of Chest Physicians. They recommend 
anticoagulation for at least three weeks prior to DC cardioversion and for a further four 
weeks following a successful procedure. Warfarin treatment was used with a target 
intemational normalised ratio (INR) of 2.0 - 3.0. This was achieved via the anticoagulant 
clinic at North Tyneside General Hospital by frequent capillary sampling and dose 
adjustment. A further whole blood estimation of INR was made twenty-four hours prior to 
cardioversion to ensure adequate anticoagulation at the time of the procedure with the 
procedure being postponed in patients whose INR was less than 1.5. 
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2.7 Transoesophageal Echocardiography 
All patients had a transoesophageal. echocardiogram prior to DC cardioversion. 
Patients attended the coronary care unit of North Tyneside General having fasted for at 
least six hours prior to the procedure. An anaesthetic assessment was performed to confirm 
that the patient was suitable for general anaesthesia. An 18 gauge intravenous cannulae 
was inserted into a vein on the back of the right hand. Blood pressure, oxygen saturation 
and ECG monitonng was performed throughout the procedure. Oxygen was administered 
via nasal prongs at a rate to maintain oxygen saturation throughout the procedure. The 
patient was positioned facing slightly to the left side and the hypopharynx was sprayed 
with xylocaine topical anaesthetic. Sedation was achieved using intravenous midazolam to 
a maximum dose of 10mg. Transoesophageal echocardiography was carried out using a 
Hewlett Packard sonos 2500 and a multiplane probe (Philips Medical Systems, 
Massachusetts, USA). All cardiac chambers and valves were visualised in the standard 
manner in both the zero and 90 degree planes and any abnormalities noted. The 
measurements outlined below were performed specifically for the purpose of the study. 
The definitions used are similar to those used by previous investigators so as to allow 
comparison between studies. 
Left atrial dimensions (zero degree view) 
1. Antero-posterior diameter: Defined as the distance from the top of the sector 
angle (or the posterior wall if visible in the extreme near field) through the 
centre of the left atrium to the centre of the mitral valve. 
2. Lateral diameter: Defined as the distance from the atrial septum through the 
atnal centre to the lateral wall of the atria measured perpendicular to the antero- 
posterior diameter. 
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Left atrial appendage measurements ( 90 degree view) 
1. Left atrial. appendage area: Defined as the area encompassed by a line from the 
tissue fold that separates the left atrial. appendage from the left atrium to the 
opposite pole of the appendage orifice and the borders of the left atrial 
appendage. 
Presence of thrombus and echo contrast 
1. Presence of thrombus: A thrombus was said to be present when a discrete mass 
could be visualised consistently with a different echo texture to the surrounding 
tissue. 
2. Presence of spontaneous echo contrast: Spontaneous echo contrast was said to 
be present when the typical "smoke" like pattern could be consistently 
identified. 
Flow measurements 
1. Left atrial appendage doppler flow velocity: The average peak antegrade flow 
taken from five consecutive beats with relatively stable RR intervals. Flow was 
measured at a point I cm below the midpoint of the appendage orifice using 
doppler echocardiography. Taken from 90-degree view. 
2. Mitral valve doppler flow velocity: The peak diastolic transmitral. flow velocity 
averaged over five consecutive beats with relatively stable R-R intervals. 
Measurements were made at a point I cm above the mid point of the mitral 
valve orifice in the zero degree view. 
3. Pulmonary vein doppler flow velocity. The peak pulmonary venous flow was 
measured in the left upper pulmonary vein. Five consecutive peaks were 
averaged using relatively stable R-R intervals. Measurements were made in the 
90-degree plane. 
67 
All measurements were made from points agreed by two operators. TOE studies 
were recorded onto standard VHS video cassette. 
2.8 DC Cardioversion 
Patients who had no evidence of thrombus on transoesophageal echo proceeded 
directly to DC cardioversion. An anaesthetist administered a short acting general 
anaesthetic after pre-oxygenating the patient by way of a bag and mask. The choice of 
anaesthetic agent was left at the discretion of the anaesthetist but propofol was the drug 
most frequently used. 
Once the patient was fully anaesthetised, two gel-coated pads (3M Healthcare, St 
Paul, USA. ) were placed on the thorax. One pad was placed to the right of the upper part of 
the sternum with the other being placed at the apex. Synchronised monophasic DC shocks 
were delivered via electrode paddles and downward pressure applied during shock delivery 
(Code master XL+, Philips Medical Systems, Massachusetts, USA). The initial shock 
energy used was I OOJ. If this was unsuccessful further shocks were delivered in a standard 
step up protocol of 200J, 360J, 360J until either sinus rhythm was achieved or a maximum 
of four shocks were delivered. A successful DC cardioversion was said to have taken place 
if sinus rhythm was restored at the time of defibrillation. Patients who achieved sinus 
rhythm had a 12 lead ECG recorded and were allowed to recover spontaneously prior to 
further investigations being carried out. Rate limiting medication was stopped prior to 
discharge. Patients who failed cardioversion were removed from subsequent follow up and 
further treatment offered on an individual patient basis as required. 
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2.9 Initial Signal Averaging 
11 wave signal averaging was perfon-ned in all patients following successful DC 
cardioversion. The initial recording was obtained two hours tollowing cardiovcrsion. 
Patients were asked to lay still and avoid talking during acquisition and all unnecessary 
electrical equipment was removed from the room. The patients skin was cleaned with 
alcohol wipes and lightly abraded to ensure good electrical contact. Self-adhesive 
electrodes (Biotab, MSB, Wiltshire. IJK. ) were then placed on the thorax in a Frank X, Yý 
Z orthogonal configuration (see below). 
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Figure I Diagram illustrating lead position during PSAL, CG recording (Courtesy of Marquette 
clectronics) 
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Orthogonal plane (leads) Position of electrodes 
X (leads I and C6) I Left and right mid axillary lines at the fil'th 
intercostal space. 
Y (L and C4) I Left nildclavicular fine. just interior to clavicle 
and at level of umbilicus 
Z (H and M) I fourth intercostal space. lust to the left ofthe 
sternum and aqjacent to the vertebral body at the 
same level 
Table 7 Position of FCG leads cluring P wave signal averaging 
Recordings were made using a MAC 5000 FCG machine equipped with the 
Signal-Averaged I ligh Resolution P-Wave Analysis Program (Phi Res, Marquette 
Electronics. Milwaukee, Wisconsin). This program allows signals to be amplified and 
digitised at a sampling rate of I 00014z. The QRST portion ofthe FCG signal is subtracted 
from the recording and following band pass filtering at 40-250 1 lz the 11 wave is detected. 
A 11-wave template is automatically formed. 'rhe template is then used to identII'v all 11 
waves which match the template with a correlation coefficient of greater than 0.95. These 
11 wave signals are averaged until the desired noise level is reached. Throughout this study 
all P-wave signal average recordings were continued until a noise level of less than 0.3[tV 
was achieved. The duration of the unfiltered and filtered 11 wave were calculated 
automatically along with the root mean squared voltages for the last 20,30 and 40 
millisecond portions of the 1) wave. The number of beats averaged in order to achieve the 
desired noise level was also noted. All signal averaged ECG recordings were stored on 
floppy disc. 
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Following signal averaging patients were allowed home in the company of a 
relative once fully recovered from the effects of anaesthesia. Rate limiting medications, 
such as digoxin and beta-blockers, were stopped and patients were asked to return to the 
outpatient clinic 2 days later for review. 
2.10 Forty Eight Hour Review 
Patients were asked not to eat, drink or smoke for three hours prior to attending the 
clinic for review and a standard 12 lead ECG was recorded. Patients who had relapsed to 
atrial fibrillation within the 48-hour period were removed from subsequent follow up and 
offered specific treatment as necessary. 
A repeat P wave signal averaged ECG was performed in all patients who remained 
in sinus rhythm as described earlier. Patients were then fitted with a 24 hour ECG recorder 
(Tracker 2, Reynolds Medical, Hertford, UK. ) in order to allow heart rate variability to be 
calculated. Recordings were carried out in a room free from exogenous stimuli and at the 
same time of day (3pm). The patients skin was cleaned with alcoholic wipes prior to self 
adhesive electrodes being attached in a standard lead configuration (see below). Patients 
were asked to rest in a supine position, to remain as still as possible and not to talk for 
thirty minutes. Recording was commenced after fifteen minutes in order to allow true 
resting heart rate to be reached. Three consecutive five-minute recordings were obtained 
for frequency domain spectral analysis and recording was continued to allow time domain 
analysis to be carried out on the entire 24-hour recording. All recordings were stored on 
standard audio cassette. Patients returned to the ECG department to have the tracker 
removed. Warfarin therapy was stopped one month later in those patients maintaining 
sinus rhythm. 
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Figure 2 Lead position used for heart rate variability recordings. (illustration courtesy of 
Reynolds Medical) 
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2.10.1 Heart Rate Variability Analysis 
The 24 hour ECG recordings were analysed using the Pathfinder system and 
Research Tools HRV analysis software (Reynolds Medical, Hertford, UK. ). All recordings 
were manually reviewed. Non sinus complexes and ectopic beats were removed prior to 
analysis. All RR intervals that differed by more than 20% from the preceding interval were 
removed automatically. Frequency domain spectral analysis was carried out using the 
commercially available Research Tools Software (Reynolds Medical, Hertford, UK. ). This 
software analyses the frequency domain component of heart rate variability using Fast 
Fourier Transformation. Three consecutive five minute periods were used for analysis and 
mean values calculated for VLF power, LF power, HF power over the fifteen minute 
period. In addition mean total power, mean normalised LF power, mean normalised HF 
power and the mean LWHF ratio were obtained. Waterfall plots were generated from this 
data. 
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Figure 3 Example of a heart rate variability waterfall plot 
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Fime domain analysis was performed on the whole recording following manual 
editing. The time domain variables calculated are shown in the table below. 
Variable (units) Definition 
mean RR duration (ms) Mean RR duration over entire recording 
SNN50 inc Number of RR intervals greater than 50msec longer than 
the preceding RR interval 
SNN50 dec Number oI'RR intervals greater than 50nisec shorter than 
the preceding RR interval 
SNN50 total Total number of RR intervals with change ot'greater than 
50 msec compared to preceding RR interval 
SNN6% dec Number of RR intervals with decrease in duration ol'6% or 
more compared to previous RR interval 
SNN6% total Number of RR intervals with a change in duration ol'6% or 
more compared to previous RR interval 
SDNN (ms) Standard deviation ofall normal RR intervals in the 24 
hour recording. 
SDANN (ms) Standard deviation ofthe mean ofall 5 min segments of 
normal RR intervals ofa 24 hour recording. 
SDNNi Mean ofthe standard deviations ofall NN intervals lor all 
5 minute segments of a 24 hour recording 
RMSSD (ms) The root mean square of successive differences in RR 
intervals 
Table 8 Time domain heart rate variability measurements used 
2.11 Follow Up 
Patients were reviewed every three months in the outpatient department lor a 
maximum of six months. At each follow up visit rhythm was assessed by means of a 
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standard 12 lead ECG. Patients reverting to atrial. fibrillation were removed from the study 
and further therapy commenced where appropriate. Those patients who remained in sinus 
rhythm for six months were said to have reached the end point of the study. 
2.12 Statistical Analysis 
All continuous variables that were normally distributed were compared using the 
students' t test. Continuous variables that were not normally distributed were compared 
using the Mann Whitney U test. Ap value of less than 0.05 was taken to be statistically 
significant for both tests. Categorical data was analysed by means of the Fishers exact test 
where any cell in a two by two table had a frequency of 5 or less. Where categorical data 
was analysed and all the cells in the two by two table had a frequency greater than five 
Pearsons Chi square was used. Again ap value of less than 0.05 was taken to be 
statistically significant. 
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3 RESULTS 
3.1 Patient characteristics 
3.1.1 Number of patients recruited 
One hundred and ten patients were referred for possible inclusion in the study over 
an eighteen month period. Four patients declined the offer to take part and a further six 
patients were excluded due to significant valvular disease. 
Of the one hundred patients initially enrolled in the study ninety-one proceeded to 
transoesophageal echocardiography. The remaining nine patients being excluded during 
the anticoagulation phase of the protocol. This was due to spontaneous reversion to sinus 
rhythm in 5 patients (5%), 4 prior to transoesophageal echocardiography and one during 
the procedure. Two patients were found to have thyrotoxicosis and a further two were 
found to have significant renal impain-nent making them unsuitable for a general 
anaesthetic. 
3.1.2 Patient age and sex 
The average age of all the patients included in the study was 71 years. The 
youngest person recruited was 33 years old and the oldest 93 years. The diagram below 
shows the age distribution for the whole study population (see below). 
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Figure 4 Age range of study patients 
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Fifty six of the ninety one patients were male (64.8%). There is a clear age 
difference between the sexes with women generally being older at the time of presentation. 
The age distribution of each sex is displayed below. The mean age for women included 
was 76.1 years (SD 6.7) compared to 68.0 years (SD 9.9) for men (p<0.00 1). 
77 
Age Distribution of Men Enrolled 
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3.1.3 Comorbidity 
A detailed past medical history was obtained on enrolment to the StUdy. The table 
below shows the frequency of previous medical diagnoses at the time of enrolment into the 
study condition. Hypertension was present in around one quarter ofthe patients recruited. 
Four patients had previously undergone DC cardioversion, two for atrial flutter and two t1or 
atrial fibrillation. 
Diagnosis Number of Patients ('YO of total) 
Hypertension 23 (25.3) 
Myocardial Infarction 
Previous DC cardioversion 
6(6.6) 
4(4.4) 
Non Insulin Dependent Diabetes 4(4.4) 
Chronic Airways Disease 4(4.4) 
1'reated Hypothyroidism 2(2.2) 
Insulin Dependent Diabetes 1 (1.1) 
Deep VeinThrombosis 1 (1.1) 
Sarcoidosis 
Primary Biliary Cirrhosis 1 (1.1) 
Prostate Carcinoma 1 (1.1) 
Rheumatoid Arthritis 
Table 9 Comorbidity of'patients enrolled 
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3.1.4 Alcohol Consumption 
Alcohol consumption varied greatly within the study population. Twenty three 
patients (25.3%) did not drink alcohol at all. The consumption among the remaining sixty 
eight ranged from a single unit per week upto forty eight units per week. The graph below 
displays the level of consumption within the study population. 
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Figure 7 Histogram showing alcohol intake of study patients 
Std. Dev = 8.76 
Mean =9 
N= 91.00 
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3.1.5 Smoking 
Sixty eight of the ninety one patients enrolled were non smokers at the time of 
entry into the study. Of this group fifteen had stopped smoking between one and six 
months prior to entry. The remaining twenty three patients were smoking at time of 
enrolment. The smokers within the study smoked an average of 14.2 cigarettes per day (SD 
13.0) with the daily consumption ranging from I per day to 60 per day. 
Bar Chart of Estimated Smoking Habits 
Nu 
Estimated Number of Cigarettes Smoked Each Day 
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Medication 
All patients recruited into the study were started on warfarin therapy either by the 
referring physician or at the time of inclusion. Medication to control ventricular rate and 
eliminate symptoms was also commenced. Digoxin was the most common drug used in an 
attempt to control ventricular rate with beta-blockers proving to be the next most common 
choice. A combination of digoxin and atenolol was used in 12 patients in order to achieve 
adequate symptom control. The l'ollowing table shows the number of patients taking each 
class ol'medication. 
Medication Number of Patients 
Warfarin 91 
I)igoxin__ 69 
Beta blockers 32 
ACF, inhi bitors 12 
Thiazide diuretics 13 
Aspirin 8 
Statins 5 
Inhaled steroids 5 
Dihydropyridine calcium antagonists 5 
Loop diuretics___________ 4 
Nitrates 4 
Inhaled beta 2 agonists 5 
Sulphonylureas 4 
Thyroxine 2 
Non dihydropyridine calcium antagonists I 
Biguanides I 
Insulin I 
Others* 6 
Table 10 Medication being taken by patients enrolled 
* prednisolone, azathioprine, co-proxamol, temazepam, gold injections, paroxetine. 
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3.1.6 Duration of Atrial Fibrillation 
The exact duration of atrial fibrillation is always difficult to determine. For the 
purposes of this study the duration of atrial fibrillation was taken to be the number of days 
from either ECG confirmation of the arrhythmia or the first occurrence of the presenting 
symptom to the time of attempted DC cardioversion. Using this definition the mean 
duration of atrial fibrillation prior to attempted cardioversion was 124.5 days (SD 145.9). 
The median duration of atrial fibrillation prior to cardioversion was 87 days (range 28 - 
1095). 
3.1.7 Presenting symptom 
The patients enrolled within the study presented with a range of symptoms. 
Breathlessness was the commonest presenting symptom with 30 patients (34%) reporting 
this as the first symptom. Twenty four patients (27%) reported palpitations as the 
presenting symptom making this the second commonest symptom. A further twenty two 
patients had their atrial fibrillation detected incidentally and had no symptoms. The 
percentage of patients presenting with each symptom is displayed in the pie chart below. 
Percentage of patients with each presenting symptom 
24% 
27% 
Figure 9 Pie chart of presenting symptoms 
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3.2 Transoesophageal Echocardiography 
All Ninety one patients had a transoesophageal. echocardiography as part of the 
study. There were no complications as a result of the procedure and all the patients 
tolerated the procedure well. Four studies were incomplete due to poor image quality or 
technical difficulties and these patients were excluded from further analysis. Eighty seven 
complete TOE studies were suitable for analysis. 
3.2.1 Thrombus detection and TOE measurements 
Six patients had an intracardiac thrombus detected by TOE. All six of these thrombi 
were found in the left atrial appendage. This gives a thrombus detection rate of 6.9%. 
Although the study methods allowed DC cardioversion to be carried out in patients with an 
INR greater than 1.5 most patients had an INR at the time of cardioversion in the range 2.0 
- 3.0. The mean INR at the time of DC cardioversion in this study was 2.6 (range 1.7 to 
3.5). Those patients who had left atrial appendage thrombus detected at TOE did not have 
a statistically significantly lower INR than those patients who were free of thrombus. This 
was true both at the time of TOE and also for the four weeks prior to TOE. To assess 
whether the presence of thrombus was associated with any other TOE measurement mean 
valucs wcrc comparcd using at tcst. 
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TOE measurement Thrombus Thrombus p value 
Mean (SD) present absent (t test) 
n=6 n=81 
Left atrial AP diameter (cm) 5.18 5.26 0.726 
(0.49) (0.82) 
Left atrial transverse diameter (cm) 4.75 4.80 0.880 
(0.51) (0.69) 
Left atrial appendage area (cm) 4.63 4.85 0.703 
(1.29) (1.40) 
Mean peak left atrial appendage 20.40 26.24 0.270 
flow velocity (cm/sec) (10.62) (12.52) 
Mean peak m1tral valve flow 99.18 79.78 0.107 
velocity (cm/sec) (57.25) (25.06) 
Mean peak pulmonary vein flow 43.31 42.69 0.921 
velocity (cm/sec) (13.77) (17.11) 
Duration of AF (days) 80.83 131.38 0.022 
(29.98) (152.78) 
Table II Thrombus and TOE variables 
NoTOE measurement diftlered significantly between those patients with and 
without lell atrial appendage thrombus. Duration ofatrial fibrillation did however differ 
significantly between the two groups with those patients with a left atrial appcndigc 
thrombus having a significantly shortcr arrhythmia duration (p- 0.022). 
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3.2.2 Spontaneous echo contrast and TOE measurements 
Spontaneous echo contrast was detected in thirteen ofthe eighty one patients 
without thrombus formation (16.04%). Its relationship to othcr'FOE measurements is 
displayed in the table below. 
TOE measurements SEC SEC p value 
Mean (SD) present Absent (t test) 
n=13 n=68 
Left atrial AP diameter (cm) 5.45 5.23 ) 0.379 
(0.77) (0.83) 
- -- Left atrial transverse diameter (cm) 4.91 4.78 0.550 
(0.74) 
- 
(0.69) 
Left atrial appendage area (cmý 5.16 4.78 0.377 
(1.13) (1.45) 
Mean peak lelt atrial appendage flow 22.12 27.07 0.164 
velocity (crn/sec) (10.93) (12.74) 
Mean peak mitral valve flow velocity 69.34 81.87 0.100 
(cm/sec) (16.73) (26.01) 
Mean peak pulmonary vein flow 46.93 41.84 0.33) 1 
velocity (cm/sec) (27.06) (14.52) 
Duration ol'Al' (days) 130.46 131.57 0.975 
(100.59) (161.82) 
Fable 12 SEC aiid'l'()[-. measurements 
From these values it can be seen that patients with spontaneous echo contrast but no 
thrombus t'ormation tended to have higher left atrial appendage flow and higher peak 
mitral valve flow. This may be a reflection ofan increased preservation ofleft atrial 
function. Nonc ofthesc differenccs rcached statistical significancc. 
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3.2.3 Mean TOE measurements and sex 
Mean TOE measurements were calculated for the eighty seven full studies obtained 
and also for males and females. The mean values for each sex were normally distributed 
allowing comparison using at test. 
TOE measurement All patients Males Females p value 
Mean (SD) n=87 n=52 n=35 (t test) 
l, cl't atrial AP diameter (cm) 5.20 _ 5.41 4.87 0.011 
(0.98) (0.69) (1.24) 
Left atrial transverse diameter 4.74 4.88 4.53 0.061 
(cm) (0.85) (0.65) (1.06) 
Left atrial appendage uý(cmý) 4.77 5.07 4.33 0.023 
(1.49) (1.50) (1.36) 
Mean peak left atrial appendage 25.52 26.06 24.70 0.632 
flow velocity (cm/sce) (12.67) (12.92) (12.44) 
Mean peak mitral valve flow 80.21 73.80 99.83 0.013 
_ _vclocity(_cni/sec)_ ______ ___(29.55) 
(19.36) (38.68) 
Mean peak pulmonary vein flow 42.23 43.06 40.99 0.594 
veloc1tv (cm/scc) (17.36) (17.11) (17.90) 
Table 13 Toe measurements 
It can be seen in the table above that male patients had larger left atrial diameters 
and left atrial appendages than lemale patients. These differences reached statistical 
significance l'or mean All lelt atrial diarneter and mean LAA area. Female patients 
however had significantly greater I'low through the mitral valve. 
3.2.4 Mean TOE measurements and hypertension 
'I'o assess whether the presence ot'hypertension had an Influence on T011 
measurements mean values were compared using at test. There was no statistically 
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significant difference in any of the TOE variables measured between patients with and 
without hypertension. 
TOE measurement Hypertension Hypertension p value 
Mean (SD) present absent (t test) 
n=22 n=65 
Lel't atrial AP diameter (cm) 5.31 5.16 0.483 
(0.81) (1.03) 
Left atrial transverse diameter (cm) 4.90 4.69 0.260 
(0.68) (0.9()) 
Left atrial appendage area (cm 4.69 4.80 0.769 
(1.12) (1.59) 
Mean pe ik left atrial appendage 25.18 25.63 0.889 
flow velocity (cm/sec) (11.21) (13.20) 
Mean peak mitral valve flow 75.11 81.89 0.364 
velocity (cm/sec) (22.53) (31.49) 
Mean peak pulmonary vein flow 45.98 41.00 0.302 
___velocity 
(cm/sec) 
__ 
(19.51) (16.57) 
Table 14 Mean TOF variables and hypertension 
3.2.5 Mean TOE measurements and duration 
Pearson correlation coefficients were calculated to assess the relationship between 
duration ol'atrial librillation and the TOE measurements. Only lelt atrial appendage area 
showed a statistically significant correlation with duration ot'atrial fibrillation. This 
correlation was however relatively weak as demonstrated by the scatter plot (I igure 10) 
despite achieving a statistically signiticant p value. 
TOE measurement 
Pearso 
correlation 
coefficient 
P value 
Left atrial AP diameter (cm) 0.052 0.619 
Left atrial transverse diameter (cm) 0.123 0.262 
2 Left atrial appendage area (cm 0.243 0.025 
Mean peak lell atrial appendage flow velocity 
(cm/Scc) 
-0.105 0.337 
Mean peak mitral valve I'low velocity (cm/sec) 0.058 0.600 
Mean peak pulmonary vein flow velocity 
(cm/sec) 
0.172 0.116 
Fable 15 Correlation coefficients for duration and TOE measurements 
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Figure 10 Scatter plot of duration of atrial fibrillation and LAA area. 
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3.3 External DC Cardioversion 
3.3.1 Initial Outcome 
Eighty one patients underwent DC cardioversion following a transoesophageal 
echocardiogram that showed no evidence of intra, atrial thrombus. The overall initial 
success rate of DC cardioversion was 81.5% with 66 patients achieving sinus rhythm. The 
mean number of shocks required to achieve success was 2.53 (SD 1.04). The number of 
shocks required to achieve sinus rhythm is displayed in the chart below. Looking simply at 
the number of successes achieved it would appear that most success was achieved with two 
shocks equating to a total delivered energy level of 300J. 
Number of Successful Cardioversions 
by Number of Shocks Delivered 
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Figure II Bar chart of successful cardioversions and number of shocks 
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However when the number of patients who fail to achieve sinus rhythm with each 
DC shock is taken into account it can be seen that a greater percentage success appears to 
be achieved with each additional shock. 
Outcome of Cardioversion by Number of Shocks Delivered 
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Figure 12 Cardioversion outcome and number of shocks 
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Figure 13 Percentage success and number of shocks delivered 
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234 tota I 
Number of Shocks Delivered 
3.3.2 Complications of DC cardioversion 
The overall complication rate of DC cardioversion was very low (I In 81 ) and all 
patients were able to be discharged home the same day. Additional treatment was only 
required by one patient who was given atropine immediately 1`61lowing cardioverslon for 
bradycardia. They subsequently recovered with no ill elTects. There were no other 
complications relating to the procedure and in particular there were no thromboembolic 
complications. 
3.3.3 Factors Influencing Initial Success 
3.3.3.1 Patient Sex 
Thcrc was no significant difference in the initial success rate ofcardloversion In 
men and women. Sinus rhythm was achieved in 83.3% ol'women and 78.8% ol'men 
(p- 0.774. Fishers exact test). 
Sex Successful Unsuccessful 
cardioversion cardioversion 
_n 
('Y, )) n (%) 
Female 25(83.3) 5(16.7) 
r---M, tle 41 (78.8) 10(21.2) 
Table 16 Outcome of cardioversion in each sex 
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Y) 
Q) 
a- 
4- 
0 
CD 
IL 
100 
80 
60 
40 
20 
0 
Cardioversion Outcome 
Figure 14 Comparison of initial success by sex 
3.3.3.2 Duration of Atrial Fibrillation 
SEX 
Emale 
F--j femaie 
The number of days atrial fibrillation had been present prior to attempted 
cardioversion did not appear to influence outcome. In women the mean duration of atrial 
fibrillation was longer in those patients who had a successful cardioversion than in those 
failing to achieve sinus rhythm. The opposite was true in men where those patients who 
achieved sinus rhythm had a shorter mean duration of atrial fibrillation. Neither of these 
differences proved to be statistically significant when analysed using the students t test. 
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successful unsuccessful 
Duration of atrial fibrillation 
Mean number of days (SD) 
Sex Successful 
cardioversion 
Unsuccessful 
cardioversion 
p value 
Female 148.0 (209.0) 123.6 (118.9) 0.725 
Male 121.0 (96.0) 144.2 (195 9) , 0.711 Both 171 6) 0.893 
Table 17 Comparison of duration of atria[ fibrillation and success of cardioversion 
Figure 15 Boxplot of duration of atrial fibrillation and success of cardioversion 
Relationship Between Duration of AF 
and Outcome at Cardioversion 
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In the boxplot shown above the median duration is represented by the dark line 
within the coloured box and the borders of the box represent the interquartile range. It can 
be seen that in both sexes the interquartile ranges are similar for both patients achieving 
sinus rhythm and those having an unsuccessful cardioversion. It has been suggested by the 
Royal College of Physicians of Edinburgh that DC cardioversion should be attempted only 
in patients who have had atrial fibrillation for less than three months. In this study greater 
success was achieved in patients with a duration of atrial fibrillation greater than ninety 
days. This difference in success rates was not significant when analysed using Fishers 
exact test (p=O .41). 
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Duration of AF 90 days or less Greater than 90 days 
Successful cardioversion 
n (%) 33(76.7) 33(84.6) 
Unsuccessful cardioversion 
n (%) 10(23.3) 6(15.4) 
Table 18 Cardioversion success rates categorised by duration of AF. 
Cardloversion Outcome Categorised by Duration 
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Figure 16 Bar chart displaying outcome categorised by duration 
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Successful cardioversion Unsuccessful 
cardioversion 
Cardioversion Outcome 
3.3.3.3 Patient age 
Since a statistically significant age difference has already been demonstrated 
between male and female subjects only the influence of age within a gender can be 
evaluated. The table below shows the mean ages for patients of both sexes who underwent 
DC cardioversion and their outcome. For both male and female patients the mean age was 
higher in the group who returned to sinus rhythm at cardioversion. These differences were 
not sufficient to reach statistical significance when analysed by means of a students t test. 
Mean age 
vears (SD) 
Sex Successful 
cardioversion 
Unsuccessful 
cardioversion 
p value 
Male 70.05 (7.99) 63.82 (9.45) 0.065 
Female 77.48 (6.89) 73.80 (4.15) 0.145 
Table 19 Mean age and cardioversion outcome. 
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Figure 17 Bar chart of mean age and cardioversion outcome for each sex. 
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3.3.3.4 Comorbidity and Initial Success of Cardioversion 
The level of comorbidity within the eighty one patients who underwent DC 
cardioversion is displayed in the table below. 
Diagnosis Number of Patients 
('YO of total) 
Hypertension 22(27.2) 
Myocardial Infarction 6(7.4) 
Previous DC cardioversion 4(4.9) 
Non Insulin Dependent Diabetes 3 (3.7) 
Chronic Airways Disease 4(4.9) 
Treated I lypothyroidism 
Insulin Dependent Diabetes 
2(2.5) 
1 (1.2) 
Deep VeinThrombosis 1 (1.2) 
Primary Billary Cirrhosis 1 (1.2) 
Prostate Carcinoma 1 (1.2) 
Table 20 Co-morbidity aniong patients who underwent cardioversion 
Oftlic conditions present only hypertension was present in a suflicicrit number of 
patients to allow its effect on initial outcome ofcardioversion to be analysed. 
Ilyp 
pr 
Aension 
esent? 
Successful 
cardioversion 
Unsuccessful 
cardioversion 
Total 
YCS 17 5 22 
No 49 11 60 
Yota. 
-I 
66_____ 
__ 
16 92 
Tabic 21 Frcqucncy of hypertension and cardioversion outcome. 
When the influence ot'hypertension on the outcome of cardioversion was analysed I 
using Fishers exact test no statistically significant relationship could be demonstrated 
(p-0.587). 
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3.3.3.5 TOE variables and initial outcome of cardioversion 
Comparison was made between meanTOF values for patients achieving sinus 
rhythm at cardioversion and those remaining in atrial fibrillation. 
Successful Unsuccessful P value 
TOE measurement cardioversion cardioversion 
____Mean 
(SD) n=66 
--- --- - 
n=15 
l, ct't atrial AP diameter (cm) 5.22 5.45 0.298 
((). 8()) (0.85) 
Left atrial transverse diameter 4.72 5.09 0.054 
(cm) (0.64) ((). 80) 
Left atrial appendage area 4.75 5.26 0.195 
(cn, 2) (1.19) (2.05) 
Mean peak Ictt atrial appendage 26.35 25.29 0.759 
flow velocity (cm/sec) (12.66) (11.57) 
Mean peak m itral valve flow 79.40 93.19 0.586 
velocity (cm/sec) (25.30) (22.37) 
Mean peak pulmonary vein flow 41.35 49.37 0.060 
velocity (cm/sec) (17.22) (13.95) 
Table 22 Initial outconic and TOE measurements 
Thcrc was a tendency towards larger atrial dimensions in the failed cardioversion group 
with differences approaching statistical significance (p-0.054). Those patients who never 
achieved sinus rhythm also tended to have a higher mean peak pulmonary vein flow 
velocity than those converting to sinus rhythm (p=0.060). The error bar diagrams below 
display the mean values and 95% conlidcnce intervals for these variables. 
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Figure 19 Error bar diagram of mean pulmonary vein flow velocity and post cardioversion 
rhythm 
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3.4 Initial P Wave Signal Averaged ECG measurements 
3.4.1 Initial P wave signal averaged ECG measurements and sex 
All sixty six patients who reverted to sinus rhythin at DC cardioversion had ap 
wave signal averaged electrocardiogram recorded one hour after the procedure. No 
complications were encountered during recording. 
The table below shows the mean values and standard deviation for each variable in 
the whole patient group and also for each sex. Using a students t test the mean values were 
compared between males and 1emales. None ofthe 11 wave signal averaged ECG 
measurements recorded one hour after cardioversion differed significantly between males 
and ternales. 
PSAECC measurei 
mean 
wave duration unli 
(rns) 
wave duration tilt 
-- - 
(ms)----- 
RMS 20 (pV) 
RMS 30 ([tV) 
RMS 40 ([tV) 
Numbcr of'bcats avc 
nent All patients Male Female P value 
n=66 n=41 n=25 
tered 152.89 156.59 147.31 0.476 
(53.59) (58.66) (45.47) 
-r d e 160.92 168.59 149.42 0.118 
(49.72) (52.06) (44.48) 
4.85 4.33 5.62 0.256 
(4.03) (3.16) (5.04) 
5.43 5.10 5.92 0.491 
(4.32) (3.62) (5.25) 
6.06 6.03 6.12 0.941 
(4.57) (4.19) (5.17) 
-aged 365.12 383.05 338.23 0.467 
(246.24) (257.50) (230.62) 
Table 23 Initial (one hour) PSAFCG measurements. 
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Figure 20 Boxplots of unfiltered and filtered P wave duration. 
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The boxplot diagrams above show how the median values and interquartile ranges of all 
the initial p wave signal averaged values are similar for both sexes. 
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3.5 Forty Eight Hour Review (Early Relapse) 
3.5.1 Patient characteristics and early relapse. 
All sixty six patients who had undergone succesSfUl DC cardioversion were 
reviewed at 48 hours. A standard twelve lead electrocardiogram was recordcd flor cach 
patient. Forty three patients (65.15%) were shown to have maintained sinus rhythni with I 
the remaining twenty three (34.85%) relapsing to atrial fibrillation. The characteristics of' 
this early relapse group are displayed in the table below. 
Sinus rhythm Atrial fibrillation 
at 48 hours at 48 hours 
Number of patients 43) 23 
(%) (65.15) (34.85) 
Number of males 30 1 () 
(%) (75%) (25%) 
Number of Females 13 13 
(%) (50%) (50%) 
Number with hypertension 12 5 
(0/0 (70.59%) (29.41%) 
Mean age years 73.98 70.96 
(Sl)) (7.47) (9.67) 
Duration of AF prior to 141.76 112.48 
cardioversion (177.45) (72.42) 
mean days (SD) 
Fablc 24 Comparison ot'paticnt charactcristics by rhytilm at forty eight hours 
The influence ot'gender on rhythm at forty eight hours was tested using the Pearson 
chi square test. Malc patients who had a successful cardioversion were statisticaliv more I 
likely to be in sinus rhythm at florty eight hours than females (pA. 027). 
No statistically significant difference in either mean age (p-0.353) or mean duration of 
atrial fibrillation (p---0.202) could be demonstrated by means of a students t test. 
Fhe same was true tor hypertension with no statistically significant relationship being 
demonstrated between hypertension and rhythm at 48 hours (p=0.769, Fishers exact test) 
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3.5.2 TOE measurements and early relapse. 
The table below shows the nieanTOF values Ior those patients who relapsed to 
atrial fibrillation within forty eight hours ol'a successful cardioversion compared with 
patients maintaining sinus rhythm. 
Sinus rhythm Ah 
TOE measurement at 48 hours fibrill 
Mean (SD) at 48 
n=43 n= 
Left atrial AP diameter (cm) 5.27 5. 
- - 
(0.7 8) (t). ý 
Left atrial transverse diameter 4.80 4. ' 
(cm) (0.59) 
--(0., Left atrial appendage area 4.79 4. ' 
(cm) (1.29) 
Mean peak left atrial 26.45 26. 
appendage flow velocity (13.29) (11. 
(cm/sec) 
_ Mean peak mitral valve flow 83.98 71. 
velocity (cm/sec) (18. 
Mean peak pulmonary vein 41.29 41. 
_ 
flow velocity (cm/sec) (19.02) (1-6. 
Table 25 Mean 'FOE measurements and 48 11OUrs rhythin. 
ial 
ation p va I ue 
iours 
B 
2 0.496 
: 4) 
19 0.203 
F2) 
10 0.820 
12) 
19 0.933 
')5 0.048 
46) 
46 0.961) 
)3) 
Only mean mitral valve I'low velocity differed significantly between the t%A'O gl-OLIPS 
with those patients maintaining sinus rhythm having the greater mean llovk. Mcan lelt atrial 
diameter did not differ significantly between patients maintaining smus rhythm and those 
relapsing to atrial fibrillation. This would suggest that left atrial diameter is more closcIN 
linked to initial success at cardioversion rather than being a useful marker Ot'SUbscquent 
relapse. The diagram below displays the mean mitral llm, ý, velocities and Ille 951ýO 
confidence intervals for the two groups. 
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Figure 22 Error bar diagram of mean mitral valve flow velocity and forty eight hour rhythm. 
This diagram shows that there is a clear difference in mean mitral valve flow 
velocity between the two groups as measured by means of TOE prior to cardioversion. 
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3.5.3 Initial P Wave Signal ECG Recordings And Early Relapse 
Patients were divided into those maintaining sinus rhythm at 48 hours and those 
relapsing to atrial fibrillation and mean initial p wave signal averaged measurements 
calculated for each group. Comparison was made using a students t test. 
Initial P wave signal Sinus rhythm Atrial fibrillation alue 
averaged ECG' parameter at 48 hours at 48 hours 
Mean n=43 = 
1) wave duration unfiltered 153.42 151.82 0.898 
(ms) (59.83) (39.88) 
11 wave duration filtered 162.33 158.18 0.727 
(ms) (54.75) (39.06) 
RMS 20 ([tV) 5.21 4.14 0.242 
(4.53) (2.77) 
RMS 30 (ýtV) 5.84 4.64 0.237 
(4.76) (3.26) 
RMS 40 (pV) 6.53 5.14 0.192 
(5.03) (3.43) 
Number of beats averaged 385.95 324.41 0.299 
(267.14) (198.58) 
Fable 26 Initial p wave signal average parameters and 48 hour rhythm. 
No statistically significant difference in initial PSAECG indices could be 
demonstrated between patients who relapsed to atrial I ibrillation within 48 hours and those 
maintaining sinus rhythm. This is clearly demonstrated by the boxplots displayed below. 
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Figure 23 Boxplot of initial PSAECG p wave duration and 48 hour rhythm 
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Figure 24 Boxplot of initial PSAECG root mean squared voltages and 48 hour 
rhythm 
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3.6 Second P Wave Signal Averaged ECG measurements. 
All patients who remained in sinus rhythm at forty eight hours had a second p wave 
signal averaged ECG recorded. 
3.6.1 Second P Wave Signal Averaged ECG Measurements and Sex. 
The table below shows the mean values ofthe second p wave signal averaged FVG 
measurements taken 48 hours after DC cardioversion. Values for all patients maintaining 
sinus rhythm to 48 hours and those for men and women are displayed. 
Second PSAEC(; measurement All patients Male Female P value 
mean n= 43 n= 30 n= 13 
1) wave duration unfiltered (rns) 145.77 152.13 131.08 0.096 
(50.07) (57.06) (23.88) 
11 wave duration filtcred 151.33 157.90 136.39 0.089 
(MS) (48.56) (54.74) (25.82) 
RMS 20 (pV) 4.51 4.20 5.23 0.381 
(2.97) (2.57) (3.77) 
RMS 30 (pV) 5.70 5.23 6.77 0.326 
(3.70) (2.87) (5.12) 
RMS 40 (pV) 6.09 5.77 6.95 0.452 
(3.63) (3.15) (4.62) 
Number ol'bcats averaged 359.60 338.20 409.00 0.449 
(237.22) (206.51) (300.17) 
Table 27 Second (48 hour) PSAFICG measurements. 
Thcrc was no statistically significant difference in any of the second p wave signal 
averagcd FICG nicasuremcnts bctwcen nien and women. 
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3.6.2 Comparison of Initial and Second P Wave Signal Averaged ECG. 
Fhe timing of'p wave signal averaging t1ollowing DC cardiovcrsion may influence 
its role in predicting relapse to atrial fibrillation. Comparison was made between initial 
signal averaging and the forty eight hour measurement in order to determine whether these 
measurements were effected by time. Measurements were analysed by means of a paired t 
test 
Initial P wave signal Second P wave signal 
averaged ECG averaged ECG Paired t 
Mean Mean test 
(SD) (Sl)) p value 
11 wave duration 153.42 145.77 0.358 
L111filtmd (ms) (59.83) (50.07) 
11 wavc duration 162.33 151.33 0.124 
) fi I tered (ni s (54.75) (48.56) 
_ _ RMS 20 (ýN) 5.21 4.51 0.220 
(4.53) (2.97) 
RMS 30 (ýN) 5.84 5.70 0.803 
(4.76) (3.70) 
RMS 40 (ýN) 6.53 6.09 0.470 
( 5.03) (3.63) 
Nuinbcr ofbcats 385.95 359.60 0.587 
avcraged (267.14) (237.22) 
Table 28'Fable comparing initial and second PSAECG variables for patients maintaining sinus 
r1whin to 48 hours. 
No statistically signiticant difTerence was shown between initial PSAECG 
measurements and those recorded at 48 hours. This would suggest that PSAECG 
measuremcnts are Linat'fcctcd by the time at which they are performed within the first forty 
cight hours l'ollowing succcssful DC cardioversion ofatrial librillation. 
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3.7 Heart Rate Variability Measurements. 
3.7.1 Number Available For Analysis 
All forty three patients who maintained sinus rhythm to 49 hours had their heart 
rate variability measured. Four of these recordings were found to be unsuitable for 
analysis. This was due to mechanical failure in one recording and poor quality ot'recording 
in a further three. This meant that only thirty nine recordings were suitable for editing. A 
further lour recordings were fiound to have a significant proportion unsuitable for analysis 
such that greater than 25% ofthe recording was removed by editing. These recordings 
were excluded from analysis leaving a total of thirty five recordings were used for analysis. 
3.7.2 Time Domain Analysis 
Time dornam analysis was performed on the entire twenty four hour recording 
l'ollowing manual editing. Mean RR, SDANN and RMSSD were normally distributed the 
mean values and standard deviations flor these parameters are displayed below. 
Variable (units Mean SD 
Mcan RR (nis) 880.46 138.11 
_ SDANN (ms) 106.89 
d 
33.87 
RMSSD (MS) 62.49 30.35 
Table 29 Normally distributed time domain heart rate variability measurements. 
The remaining time domain variables were found to have a skewed distribution. 
The median value and range of these values are displayed in the table below. 
Variable (units) 
. 
Median Range 
. .... SNN50 mc 4006 27708 
_____ SNN50 dec 5482 38371 
SN N50 total 9920 66079 
_ SNN6'Yo inc 4837 30413 
SNN6()/o dec 4810 41056 
SNN6% total 9877 _ 71400 
SI)NN (ms) 122 134 
__ __ SDNNI (ms) __ 56 77 
Table 30 Skewed distributed time domain heart rate variability measurements 
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3.7.2.1 Time Domain Analysis and Sex 
Comparison of time domain heart rate variability between males and 1'emales was 
carried out using the students t test for normally distributed variables and the Mann 
Whitney U test for those variables that were not nomially distributed. 
Heart rate Males Females p value 
variability n=27 n=8 Students t test 
measure Mean (SD) Mean (Sl)) 
_(u 
n its) 
Mean RR (ms) 891.07 844.63 0.354 
(145.05) (112.23) 
SDANN (ms) 105.07 113.00 0.516 
(35.81) (27.49) 
RMSSD (ms) 62.89 61.13 0.892 
(30.52) (31.78) 
Fable 31 Comparison ol'normally distributed time domain variables between sexes 
Variable (units) Males n=27 Females n=8 p value 
Median (range) Median (range) Mann Whitney 
SNN50 inc 3766 5085.50 0.409 
(25966) (27097) 
SNN50 dec 5482 6364 0.556 
(30651) (36504) 
SNN50 total 9920 11449.5 0.582 
(56927) (3591) 
SNN6% inc 4428 5998.5 0.480 
(28771) (2839) 
SNN6% dcc 4810 6609.5 0.504 
(32_0_3 (39330) 
SNN6% total 6937 12936 0.504 
(60733) (69169) 
SDNN (ms) 122 121 0.984 
(134) (77) 
SDNNi (ms) 57 50 0.906 
(72) (68) 
['able 32Cornparison of non-normally distributed time domain variables by sex. 
When comparison was made between males and fernales no statistically significant 
difference could be found in any ofthe time dornam variables studied. 
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Figure 25 Boxplot comparing time domain variables for each sex. 
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Figure 26 Boxplots comparing RMSSD, SDANN and Mean RR between sexes. 
3.7.2.2 Time Domain Analysis and Hypertension 
To determine ifthe presence of hypertension had an effect on time domain 
variables studied comparison was made between those patients with and without 
hypertension. 
Heart rate Hypertension Hypertension p value 
variability measure present absent 
(units) n= 12 n=23 Students t 
Mean (SD) Mean (SD) test 
Mewi RR (nis) 869.00 (126.30) 891.82 (147.36) 0 . 639 
; DANN (ms) 110.59 (32.70) 106.18 (35.35) 0.719 
RMSSD (ms) 61.25 (35.91) 64.05 (28.18) 0.918 
Table 33 Comparison ot'nornially distributed time domain variables by hypertension. 
Variable (units) Hypertension 
present 
Median (range) 
Hypertension 
absent 
Median (range) 
p value 
Mann 
Whitney U 
SNN50 inc 3721.50 (27604) 4610.50 (25966) 0.449 
SNN50 dec 
___ _____4248.5 - 
(37 
-7- 
78) 6637(30651) 0.471 
_ NN50 total S 7539.5 (65254) 11892.5 (56927) 0.349 
- SNN6% inc 4730(30413) 4965(28702) 0.943 
SNN6% dec 31 
- 
45(40909) 6569.5 (32031) 0.589 
SNN6% total 6590(71322) 11669(60733) __ 0.564 
SDNN (MS) 134(131) 119.5(128) 0.482 
SDNNi (nis) 57(77) 55 (71) 0.928 
I'able 34 Comparison of time domain variables for normotensive and hypertensive patients. 
No statistically significant difference was found in any time domain variable 
between those patients with and without hypertension. 
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3.7.3 Frequency domain analysis 
Frequency domain analysis was performed on three consecutive tive minute 
periods under standardised conditions. The mean values and standard deviations for each 
variable are displayed below. 
Frequency domain variable Mean Standard deviation 
Mean I-Fpower 148.9 1 227.68 
Mean lIF power 117.07 123.18 
Mean total power 819.52 907.10 
Mean normalised U'power 40.45 15.97 
Mean normalised HF power 35.59 18.12 
Mean LF/H F ratio 1.118 0.609 
Table 35 Frequency domain licart rate variabilitN. 
3.7.3.1 Frequency domain analysis and sex 
To determine whether there was a difference in frequency domain characteristics 
between the sexes the mean values were compared using a students t test. No statistically 
significant difference was observed between the sexes. 
Frequency domain Males Females P value 
variable_____ Mean (Sl))- 
--Mean 
(Sl 
Mean I. Fpower 15' ). 40 135.92 0.841 
(254.71) (131.61) 
Mean IIF power 114.86 123.45 0.864 
(116.59) (148.12) 
-Wantotal power 855.53 715.49 0.687 
(1027.35) (427.03) 
Mean normalised LF 40.73 39.64 0.862 
power (18.02) (7.38) 
Mean norniallsed IIF 36.15 33.95 0.750 
power (20.67) (7.51) 
Mean LF/I IF ratio 1.151 1.024 0.589 
(0.671) (0.395) 
Table 36 Comparison off'requency dornain heart rate variability by sex. 
Fhis lack ot'diil'ercncc is easily appreciated when viewed as a boxplot with the 
boxes Ilor each sex showing considerable overlap. 
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Figure 28 Boxplot showing median and interquartile range of normalised power for each sex 
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3.7.3.2 Frequency domain and hypertension 
To determine whether the presence of hypertension had a significant influence on 
frequency domain measurement ofheart rate variability the mean values lor patients with 
and without hypertension were compared. 
Frequency domain variable Hypertension Hypertension P value 
present absent 
Mean (Sl))_ Mean (Sl)) 
Mean fTpower 135.46 156.86 0.786 
(134.00) (271.09) 
Mean Iit-power 106.44 123.35 0.701 
(106.64) (134.00) 
Mean total power 657.99 915.02 0.421 
(796.12) (971.75) 
Wan normalised I. Fpower 44.50 38.06 0.257 
(13.90) (16.77) 
Mein normalised HF power 36.81 34.87 0.758 
(13.29) (20.71) 
Mean LF/I IF ratio 1.097 1.131 0.869 
(0_. 442)_ (0_. 699)_ 
Table 37 Comparison offrequency domain heart rate variability and hypertension. 
In our popuiation the presence ol'hyperlension did not appear to influence 
frequency domain nicasures ofheart rate variability as no statistically significant differcrice 
could be l'ound between the two groups. 
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3.8 Three Month Review 
All forty three patients who were in sinus rhythm at 48 hours attended for review at 
three months. The table below outlines the patient characteristics by rhythm at three 
months. 
Sinus rhythm at Atrial fibrillation 
three months at three months 
Number of patients 18 25 
(%) (41.86%) (58.14%) 
Number ofmales 14 16 
(46.67%) (53.33%) 
Number oftemales 4 9 
(%) (30.77%) (69.23%) 
Number with hypertension 6 12 
(%) (33.33%) (66.67%) 
Mean age years 71.67 75.72 
(7.19) (7.20) 
Duration ol'AF prior to 104.44 167.72 
cardioversion (44.93) (225.03) 
mean days (S D) 
Table 38 Patient characteristics and rhythin at three months. 
3.8.1 Relapse at three months and gender 
When the influence of'gender was analysed no statistically significant correlation 
was l'ound between rhythm at 3 months and gender for those patients who were in sinus 
rhythm at 49 hours (pA. 503, Chi square). That is gender did not seem to influence relapse 
to atrial fibrillation in those patients who were in sinus rhythm at 49 hours. When the 
influence of'gender for all patients who had a successful cardioversion was analysed there 
was a greater tendency towards maintaining sinus rhythm in men. However statistical 
significance was not reached (p=0.08, Pearson Chi square). 
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3.8.2 Relapse at three months and age. 
Although patients who relapsed to atrial fibrillation between 48 hours and three 
months following cardioversion were on average 4 years older than those maintaining 
sinus rhythm (75.72 vs 71.67) this difference was not statistically significant when 
analysed by means of a students t test (p=0.076). When the same analysis was performed 
using all patients who had initially had a successful cardioversion the age difference was 
less pronounced. Those patients who relapsed within the three month period had a mean 
age of 73.91 years (SD 8.15) compared to 71.67 years (SD 7.19) for those maintaining 
sinus rhythm (p=0.285). 
3.8.3 Relapse at three months and duration of atrial fibrillation. 
The mean duration of atrial fibrillation for those patients who were in sinus rhythm 
at 48 hours and subsequently maintain sinus rhythm to three months was 104.44 (SD 
44.93) days compared to 167.72 (SD 225.03) days for those relapsing to atrial fibrillation 
between 48 hours and three months. This difference was not sufficient to reach statistical 
significance (p=0.248, t test). When all patients initially achieving sinus rhythm at 
cardioversion are included the mean duration for those patients relapsing within three 
months is 141.30 (SD 172.41) days. This differencc is not statistically significant (p=0.376, 
t test). 
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3.8.4 Relapse at three months and hypertension. 
Therc was no statistically significant rclationship bctwcen rclapse to atrial 
fibrillation between 48 hours and three months and hypertension (p=0.707, Chl square). 
This remained the case when all relapses within three months ofcardioversion were 
included in the analysis (p=0.498, Chi square). 
3.8.5 Three month rhythm and TOE. 
3.8.5.1 TOE and relapse between 48 hours and three months. 
In order to determine the potential role ofTOE measurements in predicting relapse 
between 48 hours and three months comparison ofTOL measurements was made between 
patients in sinus rhythm at three months and those who, having been in sinus rhythrn at 48 
hOLirs, had subsequently relapsed to atrial fibrillation. 
Atrial ribrillation 
Sinus rhvthm at between 48 hours 
TOE measurement three months and three months 
Mean (SD) p value 
n=18 n=25 
Left atria] AP diameter (cm) 5.09 5.39 0.255 
(0.90) (0.68) 
l, cl't atrial transverse diameter 4.68 4.88 0.303 
(cm) (0.67) (0.51) 
l, ct't atrial appendage area 4.97 4.64 0.446 
(c rn ) (1.47) (1.15) 
Mean peak left atrial 27.59 25.68 0.648 
appendage flow velocity (12.76) (13.85) 
(cm/sec) 
Mean peak mitral valve flow 77.98 88.05 0.235 
velocity (cm/sec) (24.69) (29.01) 
Mean peak pulmonary vein 40.66 41.72 0.850 
flow velocity (cm/sec) ( 16. ") 6) 19.3 9) 
_ _ 
Table 39 Relapse between 48 hours and three months and mean TOE measurements. 
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None of the TOE measurements differed significantly between patients relapsing to atrial 
fibrillation between forty eight hours and three months and those maintaining sinus 
rhythm. 
3.8.5.2 TOE and relapse within three months. 
To assess the role ot"FOF measurements in predicting relapse within the three 
month period meanTOE, values were compared between those patients maintaining sinus 
rhythm to three months and those relapsing at any time upto three months following 
successful cardiovcrsion. 
Sinus rhythm Atrial 
TOE measurement at three fibrillation p value 
Mean months within three 
(Sl)) months 
n_=48 
Left atrial All diameter (crn) 5.09 5.26 0.456 
(0.90) (0.76) 
Lcl't atrial transverse diameter 4.68 4.74 0.733 
(cm) (0.67) (0.63) 
1 C( Left atrial appendage area cný) 4.97 4.67 0.377 
(1.47) (1.08) 
Mean peak left atriai appendage 27.59 25.92 0.644 
flow velocity (cm/sec) (12.76) (12.73) 
_ Mean peak mitral valve Ilow 77.98 79.91 0.790 
velocity (cm/sec) (24.69) (25.74) 
Mean peak pulmonary vein flow 40.66 41.59 0.845 
velocity (cm/sec) (1 (17.67) 
Table 40 Relapse within three montlis and mean TOF variables. 
No significant ditlercrice in mean TOf- variables could be demonstrated between the two 
groups. This suggests that TOE measurements are unlikely to be usct'ul in the prediction of' 
relapse within three months. 
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3.8.6 Three month relapse and initial P wave signal averaged ECG 
3.8.6.1 Initial PSAECG and relapse between 48 hours and 3 months 
The table below shows the mean values for the initial 11 wave signal averaged FCG 
of patients who were in sinus rhythm at 48 hours categorised by rhythm at three rnonth 
review. 
In 
aver, 
wa 
)A 
Li n- 
itial P wave signal Sinus rhythm Atrial fibrillation p value 
iged ECC parameter at three months at three months 
Mean (Sl)) n=18 n=25 
ve duration Linliltcrcd 150.41 156.20 0.769 
(MS) (63.17) (59.80) 
avc duration filtered 162.47 163.00 0.976 
(MS) (54.52) (57.00) 
RMS 20 (VV) 4.06 6.00 0.161 
(3.83) (4.96) 
RMS 30 (pV) 5.00 6.48 0.334 
(4.61) (4.94) 
RMS 40 ([tV) 5.71 7.20 0.365 
(5.37) (4.87) 
iber ofbeats averaged 443.88 359.64 0.319 
(304.13) (235.95) 
/ 
Fahle 41 Initial PSAFC'G and 3 month rhythin for patients in sinus rhythm at 48 hours 
It can be seen from the table above that flor patients in sinus rhythm at 48 hours no 
initial P wave signal averaged FCG variable differed significantly between patients 
maintaining sinus rhythm to three months and those relapsing. 
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3.8.6.2 Initial PSAECG and relapse within 3 months 
The table below displays the mean initial p wave signal averaged FCG variables for 
all patients who had a successful cardioversion and their three month rhythin. 
Initial P wave signal Sinus rhythm Atrial fibrillation p value 
averaged ECG parameter at three months at three months 
Mean n=18 n=48 
P wave duration unfiltered 150.41 154.15 0.828 
(Ms) (63.17) (50.96) 
P wave duration tiltered 162.47 160.74 0.909 
(Ms) (54.52) (48.96) 
RMS 20 (ýN) 4.06 5.13 0.343 
(3.83) (4.15) 
RMS 30 ([N) 5.00 5.62 0.634 
(4.6 1 (4.30) 
RMS 40 (pV) 5.71 6.23 0.719 
(5.37) (4.34) 
Nu nber of beats averaged 443.88 343.15 0.223 
(304.13) (217.64) 
Fable 42 Initial PSAF. CG and 3 month rhythm for patients in sinus rhythin after cardioversion. 
None ofthe initial p wave signal averaged FCG variables differed significantly 
when comparison was made between patients maintaining sinus rhythm to three months 
and those relapsing within three months. This would suggest that p wave signal averaging 
perf'ormed one hour after successful cardioversion is unhelpful in predicting relapse within 
the I irst three months. 
3.8.7 Three month relapse and second P wave signal averaged ECG 
The possible role ofthe second p wave signal averaged ECG in predicting 3 month 
relapse was analysed by comparing mean values for patients maintaining sinus rhythm to 3 
months and those patients relapsing to atrial fibrillation. The table below shows these mean 
values, there standard deviation and the level ot'significance achieved when analysed using 
a students t test. 
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Second P wave signal Sinus rhythm at Atrial fibrillation p value 
averaged ECG parameter three months at three months 
Mean (SD) n=18 n=25 
11 wave duration unfiltered 150.72 142.20 0.588 
(MS) (44.53) (54.32) 
1) wave duration filtered 156.39 147.68 0.569 
(MS) (41.88) (53.40) 
RMS 20 (ýiV) 4.39 4.60 0.821 
(2.33) (3.40) 
RMS 30 (uV) 5.11 6.12 0.384 
(2.72) (4.28) 
RMS 40 ([tV) 5.50 6.52 0.370 
(2.73) (4.16) 
Number ol'beats averaged 333.94 378.08 0.548 
(226.29) (2_47.7 1 
Table 43 Second llSAECG and rhythni at three months. 
None of the differences observed achieved statistical significance. 
The lack of significant difference in any ofthe p wave signal averaged FCO 
measurements between patients relapsing to atrial fibrillation and those maintaining sinus 
rhythm suggests that p wave signal averaging has little to offer when attempting to predict 
relapse within the first three months t'()Ilowing DC cardioversion. 
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3.8.8 Three month relapse and time domain heart rate variability 
The table below shows the mean RR interval. SDANN and RMSSD for patients 
maintaining sinus rhythm at three months and those relapsing within the same time period. 
No statistically significant difference in any of these values was shown between the two 
groups. 
Heart rate variability Sinus rhythm Atria[ fibrillation p value 
measure at 3 months at 3 months 
(units) n=16 n=19 Students t test 
Mean (SD) Mean (SD) 
Mcan RR (ms) 884.00 (142.13) 877.47 (1 -3 ) 
8.47) 0.892 
SDANN (ms) 113.63 (31.24) 101.21(35.77) 0.281 
_RMSSI_)_ 
(m_s)______ 59.56 (33.64) 64.95 (27.97) 0.608 
Tablc 44 Time domain hcart ratc variability and 3 month rhythm 
Median values were calculated Ior all time domain variables that were not normally 
distributed and comparison between the two groups made by means ol'a Mann Whitney U 
test. No statistically significant diftlerence was t1ound between the two grOLIPS 
Variable (units) Sinus rhythm Atrial fibrillation at p value 
at three months three months (Mann 
Median (_ran_ge)__ 
___Median 
(range Whitney U) 
SNN50 inc 3 886 4967 0.791 
(27708) (14280) 
SNN50 dcc 5061 7120 0.741 
(38371) (30058) 
SNN50 total 9818 12087 0.716 
(66079) (44338) 
SNN6()/o inc 4633 5093 0.869 
(30354) (14986) 
SNN6% dec 4270 6186 0.446 
(41056) (30029) 
SNN6% total 8316 12046 0.509 
(71400) (45015) 
SDNN (ins) 134 109 0.227 
(128) (131) 
_SDNNi 
(ms) 54(71) 57(77) 0.643 
Table 45 Time domain heart rate variability non parametric analysis and three month rhythm. 
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3.8.9 Three month relapse and frequency domain heart rate variability 
Although large diffierences in the mean values Ilor mean VLF power and mean total 
power were found between the groups these differences did not reach statistical 
significance when analysed using the student t test. 'rhe highest mean values werc 
encountered in patients who maintained sinus rhythm. 
Frequency domain Sinus rhythm Atrial fibrillation p value 
variable at three months at three months 
n=16 n=19 
_ ____Mean _(Sl))_ Mean Vl, l, 'power 802.34 489.23) 0.314 
(1134.25) (451.38) 
Mean 1.1'power 100.61 189.59 0.223 
(52.60) (302.97) 
Mean III, ' power 106.53 125.95 0.631 
(89.40) (147.70) 
Aean total power 999.34 668.08 0.325 
(1196.82) (554.64) 
Mean normallsed 1,1, ' 42.62 38.63 0.469 
power (16.70) (15.36) 
Mean nornialiscd fil, ' 42.04 33 0.16 0.060 
power (21.75) (12.56) 
Mean I I` ratio 1.035 1.189 0.454 
Fable 46 Frequency domain heart rate variability and three nionth rhythm 
When these results are displayed in the form ofa boxplot it can be seen that there is 
considerable overlap between the sinus rhythin and atrial fibrillation groups. These results 
suggest that frequency domain measurement of heart rate variability alone is inadequate for 
the prediction ofrelapse to atrial fibrillation between 48 hours and 3 months following 
successful DC cardioversion. 
125 
3000 
1000 
2000 
ri. 
__ Sinus rhythm Atnal fibrillation 
Rhythm at three months 
Figure 31 Boxplot of mean power and three month rhythm. 
80 
60 
4U 
20 
0 
Sinus rhvthm Atrial fibrillation 
Rhythm at three months 
.2 lzý 
LL 
4ý 
LL 
Mean normalised LF 
power 
mean normalised HF 
power 
Mmean VLF power 
Mmean LF power 
Mmean HF power 
Mmean totai power 
35 
30 
2,5 
20 
15 
10 
5 
001 
Sinus rbvthm Atrial fibrillation 
Rhythm at three months 
Figure 32 a and b Boxplots of mean normalised power and mean LF/HF ratio and three month 
rhythm. 
126 
3.9 Six Month Review 
All eighteen patients who were in sinus rhythni at three months attended for revic\, \ 
at six months. Only three patients had relapsed to atrial tibrillation in this time period with 
the remaining 15 maintaining sinus rhythm. The table below shows tile patients 
characteristics divided by rhythm at six month t'ollow Lip t'()r those patients who maintained 
sinus rhythm to forty eight hours. 
Sinus rhythm at I Atrial fibrillation 
six months at six months 
Number ot'patients 15 
(%) (83.3%) (16.7%) 
Number ofmales 11 3 
(%) (78.6%) (21.4%) 
Number of females 4 0 
(%) (1()(). 0%) ((). ()%) 
Number with hypertension 6 3 
(0/0 (66.7%) (33.3%) 
Mean age years 72.60 67.00 
(Sl)) (6.93) (8.00) 
Duration of AF prior to 114.07 56.33 
cardioversion (41.63) (29.37) 
mean davs (SD) 
'Fable 47 Patient characteristics and 6 nionth rhythm 
3.9.1 Relapse at six months and gender 
The c11'ect ol'gendcr on relapse between 3 and six months was not calculated due to 
the small number of'relapses occurring during this period. Ofthe sixty six patients who had 
an initially successful cardioversion 51 had relapsed to atrial fibrillation (29 males. 22 
fiernale). The potential influence ot'gender on six month outcome was analysed using the 
Fishers exact test. No statistically significant correlation between gender and rhvthrn at six 
months could be demonstrated (p=0.369). 
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3.9.2 Relapse at six months and age 
Patients who relapsed to atrial fibrillation between three and six months tended to 
be older than those maintaining sinus rhythm (72.6 Vs 67.0) however this difference was 
not statistically significant (p=0.350). Again when all patients who had a successful 
cardioversion are included in the analysis and outcome at six months used to compare 
means the difference becomes far less pronounced (SR=72.6, AF=73.06, p=0.853). 
3.9.3 Relapse at six months and duration of atrial fibrillation 
The table above shows that those patients who were in sinus rhythm at three 
months and subsequently maintain a normal rhythm to six months had a longer duration of 
atrial fibrillation than those who relapse (114.1 Vs 56.3). This difference achieved 
statistical significance when analysed using an independent samples t test (p=0.047). when 
all patients who had an initially successful cardioversion. were included in the analysis this 
difference was reversed with patients who relapsed to atrial fibrillation having a mean 
duration of 136.25 days (SD=166.70). This difference was not statistically significant 
(p=0.391) 
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3.9.4 Six month rhythm and TOE. 
3.9.4.1 TOE and relapse between three and six months 
To determine whether TOE measurements had a role in predicting late relapse to 
atrial fibrillation comparison was made between patients who were in sinus rhythm at six 
months and those relapsing to atrial fibrillation between three and six months. 
Atrial fibrillation 
Sinus rhythm at between 48 hours 
TOE measurement six months and three months 
Mean (SID) p value 
n=15 
_n=3 Left atrial All diameter (crn) 4.98 5.96 0.434 
(0.84) (1.16) 
Left atrial transverse diameter 4.66 4.79 0.783 
(c m) (0.71) (0.47) 
Lell atrial appendage area 4.90 5.49 0.611 
(cn, 2) (1.41) (2.45) 
Mean peak lell atrial 28.25 22.68 0.579 
appendage flow velocity (13.17) (10.95) 
(cm/scc) 
Mean peak mitral valve flow 76.73 87.34 0.585 
velocity (cm/sec) (24.22) (36.57) 
Mean peak pulmonary vein 41.40 35.11 0.776 
flow velocity (crn/sec) 6.09) 
_(24.20) 
Tablc 48Rclapse bctwecii 3 and 6 montlis and mean TOE measurements 
No statistically significant difference COUld be demonstrated between patients 
relapsing to atrial fibrillation between three and six months and those maintaining sinus 
rhythm. 
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3.9.4.2 TOE measurements and relapse within six months 
To assess whether'FOE measurements had a role to play in predicting relapse to 
atrial fibrillation over the whole t'ollow up period meanTOE variables were compared 
between patients maintaining sinus rhythm to six months and those relapsing to atrial 
fibrillation at any time within the six month period. 
Atrial fibrillation 
Sinus rhythm at at any time within 
TOE measurement six months six month follow 
Mean (SD) up period p value 
n=15 n=51 
Left atrial AP diameter (cm) 4.98 5.29 0.187 
(0.84) (0.79) 
Left atrial transverse diameter 4.66 4.74 0.687 
(cm) (0.71) (0.63) 
Left atrial appendage area 4.90 4.67 0.502 
(CIII 2) (1.41) (1.10) 
Mean peak lel't atrial 28.25 26.01 0.555 
appendage flow velocity (13.17) (12.61) 
(cm/sec) 
Mean peak initral valve flow 76.73 90.81 0.598 
velocity (cm/sec) (24.22) (25.70) 
Mean peak pulmonary vein 41.40 41.38 0.996 
flow velocity (cm/sec) (16.09) (17.88) 
Table 49 Relapse within six montlis and mean TOF. measurements 
No statistically significant difference in mean TOF measurements was 
demonstrated between patients maintaining sinus rhythm for six months and those 
relapsing over the same period. 
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3.9.5 Six month relapse and initial P wave signal averaged ECG 
The table below shows the mean initial P wave signal averaged FICG values for 
patients maintaining sinus rhythm to six months and those relapsing within the six month 
follow up period. 
Initial P wave signal Sinus rhythm Atrial fibrillation p value 
averaged ECG' parameter at six months within six months 
Mean (Sl)) n=15 n=51 
1) wave duration unfiltered 149.00 148.37 0.966 
(MS) (64.25) (45.58) 
P wave duration filtered 161.40 155.22 0.654 
(MS) (55.51) (43.57) 
RMS 20 (pV) 4.27 5.33 0.376 
(3.90) (4.06) 
RMS 30 (pV) 5.13 5.89 0.568 
(4.78) (4.27) 
RMS 40 (ýN) 5.73 6.59 0.527 
(5.49) (4.27) 
Number ol'beats averaged 425.00 347.16 0.286 
(335.80) (213.43) 
Table 50 Initial I1SAFCG measurements and rhythin at six months 
No statistically significant difference in initial 11 wave signal averaged ECG 
measurement was detected between patients maintaining sinus rhythm and those relapsing 
to atria] fibrillation. 
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3.9.6 Six month relapse and second P wave signal averaged ECG 
To determine the role ofthe second p wave signal averaged ECG in predicting 
relapse between 49 hours and six months of cardioversion comparison was made between 
patients maintaining sinus rhythm and those relapsing. 
Second P wave signal Sinus rhythm at Atrial ribrillation p value 
averaged ECC parameter six months at six months 
Mean(SD) 
_n=15_ 
n=28 
1) wave duration unfiltered 143.00 131.93) - 0.283 
(MS) (27.67) (37.59) 
11 wave duration filtered 149.80 137.89 0.222 
(MS) (24.47) (37.57) 
RMS 20 (uV) 3.93 4.78 0.329 
(2.22) (3.30) 
RMS 30 (pV) 4.53 6.41 0.080 
(2.64) (4.11) 
RMS 40 ([tV) 5.00 7.04 0.040 
(2.24) (3.98) 
Number ol'beats averaged 306.60 224.30 0.279 
_(205.47) 
(268.43) 
Table 51 Second PSAECO and six month rhythin 
There was no significant difference in p wave duration between patients 
maintaining sinus rhythm and those relapsing to atrial fibrillation. However the RMS 40 
was significantly greater I'Or patients relapsing to atrial fibrillation compared to those 
maintaining sinus rhythm. Although RMS 30 also tended to be greater Ilor relapsing 
patients the dill'ercnce failed to reach statistical significance. 
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3.9.7 Six month rhythm and time domain heart rate variability 
The table below shows the mean time domain heart rate variability measurements 
for patients maintaining sinus rhythm to six months and those relapsing to atrial fibrillation 
within the same period. No statistically significant difference was found in any ofthese 
variables. 
Heart rate variability Sinus rhythm Atrial fibrillation p value 
measure at six months at six months 
(units) n=13 n=22 Students t test 
Mean (SD) Mean (SD) 
Mean RR (nis) 909.00 862.23 0.345 
(135.22) (142.17) 
SDANN (ms) 110.31 102.82 0.531 
(31.15) (35.30) 
RMSSD (ms) 54.92 66.95 0.263 
(30.57) (30.01) 
Table 52 Time domain heart rate variability and 6 month rhythm 
Median values and ranges were calculated for variables that were not normally 
distributed and a Mann Whitney test used to compare the two groups. 
Variable (units) Sinus rhyth at Atrial fibrillation p value 
six months at six months (Mann 
_ __Median 
(range Median (range) Whitney U) 
SNN50 inc 3730 4486.5 0.785 
(45511) (25966) 
SNN50 dec 4900 6637 0.413 
(45391) (29700) 
SNN50 total 9716 11003.5 0.918 
(90902) (56927) 
SNN6% inc 4429 4965 0.795 
(51661) (28712) 
SNN6% dec 3803 6569.5 0.195 
(50590) (32031) 
SNN6% total 6754 11955.5 0.246 
(102251) (60733) 
SDNN (ms) 133 113 0.394 
(131) (128) 
SDNNi (ms) 52 56.5 0.539 
(77) (71) 
Table 53 Time domain heart rate variability analysis and six month rhvtlini 
13 33 
There was no statistically significant difference in any time domain heart rate 
variability measure between the two groups. 
3.9.8 Six month relapse and frequency domain heart rate variability 
When Frequency domain heart rate variability meaSUrements were compared 
between patients maintaining sinus rhythm to six months and those relapsing to atrial 
fibrillation no statistically significant difference could be found. 
Frequency domain Sinus rhythm Atrial fibrillation P value 
variable at six months at six months 
n=13 n=22 
Mean (SD) Mean (Sl)) 
Mean Vl, l, 'power 836.04 496.58 0.328 
(1201.01) (452.6 1) 
Mean I. Fpower 106.88 __ 176.94 0.380 
(53.00) (290.24) 
Mean Ill' power 108.42 122.84 0.740 
(95.77) (140.51) 
Mean total power 1039.22 673.05 0.248 
(1265.90) (549.50) 
Mean normalised LF 44.40 37.82 0.235 
power (17.11) (14.83) 
- Mean normalised liF 41.96 31.34 - 0.136 
power (23.33) (12.53) 
Mean I+A I l' ratio 1.093 1.135 0.843 
(0.522-) (0.673) 
Table 54 Frecltiency domain heart rate variability and six nionth rhythni 
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3.9.9 Overall success rates 
Overall success rates were low with only 23% of patients who had an initially 
successful cardioversion maintaining sinus rhythm to six months. When those patients who 
underwent a failed cardioversion are included in the analysis a total of eighty one 
cardioversions were performed with 15 patients maintaining sinus rhythm to six months. 
This gives a success rate of only 18.5%. The percentages in the tables below were 
calculated using only those patients who achieved sinus rhythm at cardioversion. 
Patients Remainin g in Sinus Rhythm 
Time 
(days) 
Total 
number 
% of 
patients 
Number 
of males 
% of 
males 
Number 
of 
females 
% of 
females 
0 66 100 41 100 25 100 
2 43 65 30 73 13 52 
90 18 27 14 34 4 16 
180 15 23 11 27 3 12 
Table 55 Sinus rhythm rates at each follow up 
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Figure 33 Graph of number of patients maintaining sinus rhythm 
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A greater percentage of males maintained sinus rhythm to six months compared to 
females. This difference was shown to be statistically significant at 48 hours (p=0.027) but 
failed to reach statistical significance at any time thereafter (p=0.08). 
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Figure 34 Percentage of patients remaining in sinus rhythm 
3.9.10 Overall relapse rates 
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The table below shows the total number and percentage of patients relapsing to 
atrial fibrillation over time and also figures for each sex. 
Patients Relapsing to Atrial Fibrillation 
Time 
(days) 
Total 
number 
% of 
patients 
Number 
of males 
% of 
males 
Number 
of 
females 
% of 
females 
0 0 0 0 0 0 0 
2 23 35 10 24 13 52 
90 48 73 26 63 22 88 
180 51 77 29 71 22 88 
Table 56 Relapse rates at each follow up 
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Figure 35 Number of patients relapsing to atrial fibrillation 
When graphs of the number of patients relapsing over time are constructed it can be 
seen that by far the greatest rate of relapse occurred within the first two days following 
successful cardioversion. Following this the relapse rate slows over time. 
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Figure 36 Percentage of patients relapsing to atrial fibrillation 
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Multivariate logistic regression analysis was performed using age, prior duration of 
atrial fibrillation and all of the transoesophageal echocardiography, p wave signal averaged 
ECG and heart rate variability variables measured at each follow up stage. None of the 
variables analysed proved to be statistically significant at forty eight hours, three months or 
six months either individually or in combination. 
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4 Discussion 
0 4.1 Patient characteristics 
4.1.1 Age 
The design of the study was such that patients from all age groups were eligible for 
inclusion. This lead to an increased mean age when compared to other studies in which 
older patients were excluded. The decision to include older subjects was made in order to 
allow the results of the study to be more easily applied to normal everyday UK practice. In 
this study there was no evidence that age played a part in predicting either relapse 
following successful cardioversion or initial success. These results echo those of Carlsson 
et al who studied over a thousand patients and found no difference in initial success rates 
between patients aged 65 and over and younger subjects. (80) The fact that all patients, 
including the elderly, were able to tolerate the treatment adds weight to the theory that age 
alone should not be a barrier to attempted DC cardioversion. With this in mind it can be 
argued that older patients may in fact form a subgroup of patients in whom DC 
cardioversion should be attempted routinely since it is these patients who are most at risk 
from thromboembolic complications or side effects of pharmacological therapy. These 
older patients therefore have more to gain from a successful procedure. 
4.1'. 2 Duration of atrial fibrillation 
Our results differ from those of several other authors in that prior duration of atrial 
fibrillation was not shown to be predictive of either initial success of DC cardioversion or 
subsequent relapse to atrial fibrillation. One explanation for this is the problem of trying to 
establish the precise duration of atrial fibrillation. In our study a significant percentage of 
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patients included had no symptoms at presentation leading to inevitable errors in 
deten-nining prior duration. In this study we determined the duration of atrial fibrillation 
from either the first symptom reported by the patient or first ECG confirming the 
diagnosis. This differed from most other studies where duration of atrial fibrillation was 
determined solely on the basis of first confirmatory ECG. This approach was used in order 
to simulate everyday clinical practice where a decision as to whether to proceed to DC 
cardioversion is based on the patients' history. Another explanation for this difference is 
the difference in the patients included within the studies. ý For example in the study by 
Duytschaever et al patients taking class III antiarrhythmics were included within the study 
population and estimations of duration were made retrospectively leading to inevitable 
errors. (86) In other studies patients with atrial flutter were included within the study group 
along with those with atrial fibrillation of valvular origin. (79) Our results do not support 
the recommendations of the Royal College of Physicians of Edinburgh who, in a consensus 
statement on the role of cardioversion of atrial fibrillation, recommended DC cardioversion 
be reserved for those patients who had atrial fibrillation of less than ninety days duration or 
were highly symptomatic. In our study a greater initial success rate was achieved in those 
patients with a duration of greater than ninety days than in those with a shorter duration. 
The results of this study call into question the validity of using duration of atrial fibrillation 
as a basis for determining the suitability for DC cardioversion. 
4.2 Transoesophageal echocardiography 
4.2.1 Transoesophageal echocardiography and thrombus detection 
Despite standard warfarin therapy left atrial appendage thrombi were detected in 
almost 7% of patients imaged. This rate of thrombus detection is consistent with previous 
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studies where thrombus rates between I% and 10% have been reported. There was a 
significant trend towards shorter duration of atrial fibrillation in patients with left atrial 
appendage thrombus (p=0.022). One explanation for this is that these patients have had a 
shorter duration of warfarin therapy. Given that it frequently takes several weeks to 
achieve a stable INR it is possible that patients with a shorter duration of therapy have a 
sub therapeutic INR for a greater proportion of their therapy with an increased chance of 
thrombus formation. Patients who have had a longer duration of treatment may in fact have 
had left atrial appendage thrombi if imaged earlier in there therapy that have since resolved 
due to continued anticoagulation. 
Our results add support to the use of routine transoesophagcal echocardiography 
prior to DC cardioversion in order to reduce the theoretical risk of thromboembolic 
complications to a minimum. However transoesophageal echocardiography is not currently 
available in all centres and providing this service would require a massive increase in both 
equipment and training. Further large scale studies are required comparing a strategy 
including transoesophageal. echo to standard therapy to demonstrate that complications 
would be prevented before such investment could be recommended. 
4.2.2 Transoesophageal echocardiography and initial outcome 
To our knowledge this study is the largest to date in which the relationship between 
transoesophageal echocardiography and initial success of DC cardioversion has been 
studied. Patients failing to achieve sinus rhythm tended to have larger left atrial diameters 
as measured by transoesophageal echocardiography. Although transverse diameter 
appeared to show the greater difference neither measurement achieved statistical 
significance. We concluded that transoesophageal echocardiography did not have a role in 
predicting initial success of DC cardioversion in our population. These results are similar 
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to those of Verhorst et al who were also unable to show any relationship between variables 
measured by transoesophageal echocardiography and initial success of cardioversion. (88) 
4.2.3 Transoesophageal echocardiography and relapse 
Relapse to atrial fibrillation within the first forty eight hours following successful 
DC cardioversion was associated with a significantly lower mean mitral valve flow 
velocity (p=0.048). This may well represent a decrease in mechanical function within the 
atria of this group compared to those individuals with higher mitral valve flow, sinus 
rhythm being maintained for longer in those with preserved mechanical function. 
Examination of the confidence intervals for mean peak mitral valve flow velocity as 
displayed in fig 19 shows an overlap between the two groups with both groups having 
broad confidence intervals'. This means that although the mean velocities are statistically 
significantly different its usefulness in a clinical setting is diminished. These confidence 
intervals are likely to reduce with increasing patient numbers and allow a clinically useful 
predictive value to be determined. This may allow those patients with lower values to be 
commenced on antiarrhythmic prophylaxis at the time of transoesophageal, 
echocardiography in order to prevent early relapse. Those patients with higher mitral valve 
velocities who are unlikely to relapse within the first forty eight hours and can avoid 
unnecessary therapy with its concomitant risk of side effects. In order to test this theory an 
intervention study based on mean mitral valve velocity would be the next step. Whether an 
ability to predict and avoid early relapse would lead to a greater long tenn success is 
debatable. Maintaining sinus rhythm for the first few days following DC cardioversion 
may be all that is required to trigger a reversal of electrical remodelling and allow long 
term maintenance of sinus rhythm without long term antiarrhythmic medication. 
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The results of this study are at odds with those of Manabe et al who demonstrated a 
relationship between left atrial appendage flow velocity and relapse. (89). They found that 
left atrial appendage flow was a sensitive and specific marker for success of DC 
cardioversion. However the definition of success used in this study differed from ours. 
They defined success as maintaining sinus rhyflun for two days following DC 
cardioversion. In our study success was taken to be maintenance of sinus rhythm for one 
hour with those patients relapsing within two days labelled as early relapses. These 
differences in definition mean that the two studies are not comparable with regard to early 
relapse. These results also differ from those of Verhost et al. (88) They found that a longer 
duration of atrial fibrillation, larger left atrial size, the presence of spontaneous echo 
contrast and decreased appendage flow were associated with relapse to atrial fibrillation. 
This study differed from ours in that patients were included in the study conducted by 
Verhost et al even if they were taking class I or class III antiarrhythmic medication. This 
lead to a lower recurrence rate of 42% as compared to 77% in our study. We were unable 
to include patients taking these classes of medication due to there effects on the P wave 
signal averaged ECG. It would appear from these results that transoesophageal 
echocardiographic measurements have no role to play in predicting relapse of atrial 
fibrillation in patients who are not taking concomitant antiarrhythmic medication. These 
results are however similar to those of Perez et al. who could find no relationship between 
TOE measurements and either initial success of DC cardioversion or subsequent relapse. 
(90) 
4.3 P wave signal averaged electrocardiography 
The p wave signal averaged ECG has been studied by several groups in an attempt 
to define its role in the management of patients with atrial fibrillation. The detection of late 
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potentials in the terminal portion of the P wave when measured by signal averaging may 
represent areas of slow conduction within the atria. These slowly conducting areas may 
provide the substrate for initiation and propagation of atrial fibrillation. Detection of these 
late potentials may allow identification of those patients at highest risk of relapse following 
initially successful DC cardioversion. 
4.3.1 The evidence for a relationship between signal averaging and atrial 
fibrillation 
Guidera et al studied 15 patients with paroxysmal atrial fibrillation and compared 
both their 12 lead and signal averaged ECG with those of 15 age and sex matched control 
subjects. . (118) They 
found no difference in p wave duration on standard 12 lead ECG, 
however mean unfiltered and filtered p wave duration was significantly lengthened in those 
patients with atrial fibrillation. A study of 51 patient with atrial fibrillation following 
coronary artery bypass grafting showed similar results with no significant difference in p 
wave duration on standard 12 lead ECG and an increased signal averaged p wave duration 
compared to control subjects. (I 19) Further evidence for an association between signal 
averaged parameters and atrial fibrillation was provided by Villani et al. (120) In a study of 
40 patients (20 with atrial fibrillation) they found that an increase in p wave dispersion and 
the p wave dispersion index (p wave dispersion index = {p duration (X, Y, Z, leads) S. D. / 
mean value }x 100 ) were significantly associated with episodes of atrial fibrillation. 
There was no significant difference in root mean square voltage of the last 20 milliseconds 
of the p wave (RMS20). 
Several groups have considered the use of P wave signal averaging to predict the 
relapse to atrial fibrillation following initially successful DC cardioversion. Opolski et al 
recorded signal averaged ECG in 35 patients following DC cardioversion and found that 
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the II patients who relapsed into atrial fibrillation had a significantly longer p wave 
duration(I 2 1). Stafford et al. produced similar data in patients who had relapsed following 
internal cardioversion. (I 19) One of the largest published series is that of Aytemir et al who 
measured p wave signal averaged ECG in 73 patients following cardioversion. (122) They 
also found significant differences in p wave duration with patients who relapsed showing 
longer p wave duration. 
4.3.2 The evidence against a relationship between signal averaging and 
atrial fibrillation 
Despite the positive results outlined above there is still some debate about the 
association between signal averaged p wave duration and atrial fibrillation with several 
groups unable to show a relationship. Frost et al looked at p wave duration and 
morphology of 189 patients undergoing coronary artery bypass grafting of which 42 
developed atrial fibrillation. (123) No significant relationship was found between p wave 
duration or morphology and the likelihood of an episode of atrial fibrillation. Turrito et al 
used several variables including p wave duration to attempt to risk stratify patients with 
regard to atrial tachyarrhythmias. . (124) Only left atrial AP diameter was found to be a 
useful predictor of arrhythmia recurrence. 
4.3.3 Possible causes of conflicting results 
Both the lack of standardisation and problems with reproducibility of the p wave 
signal averaged ECG have been proposed as possible causes for the different outcomes in 
the above studies. The technique has, however, been shown to have a high degree of short 
and medium term reproducibility. (125) Another suggested reason for these conflicting 
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outcomes is the filtering method used. Signal averaged signals can be filtered, prior to 
analysis, by a number of different methods including unidirectional, bi-directional, finite 
impulse response, least-squares fit and spectral (Fourier) filters. Ehlert et al studied these 
different filtering processes and concluded that least-squares fit filtering with a bandwidth 
of 29-250 Hz and QRS triggering provided the most reliable results. (126) 
A further discrepancy between the various studies would appear to be the 
antidysrhythmic medication at the time of inclusion. It has been shown that class I and 
class III agents change the characteristics of the p wave signal averaged ECG. However in 
many of the studies these medications were used in some or all of the patients enrolled. 
This may help to explain the inconsistency of the results obtained. (I 11,127-129) 
4.3.4 P wave signal averaged ECG : Our experience 
Our study currently represents one of the largest series in which p wave signal 
averaging has been performed following DC cardioversion. These recordings were made 
free from many of the confounding factors such as class I and class III antiarrhythmic 
medication that were present in many of the previous studies. We were unable to show any 
relationship between p wave signal averaged ECG variables and relapse to atrial 
fibrillation. These results add further weight to the body of evidence suggesting that P 
wave signal averaging has little to offer when trying to predict relapse of atrial fibrillation 
following successful DC cardioversion of chronic atrial fibrillation. 
By comparing values obtained at I hour and 48 hours we have attempted to 
determine whether the timing of the recording is responsible for the failure to detect a 
difference. No statistical difference was found in any of the I hour and 48 hour variables 
when they were compared by means of a paired t test leading to the conclusion that the 
timing of recording within this period is not crucial. The possibility that our recordings 
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were obtained outside the optimum time frame for detecting a difference would appear to 
be refuted by the fact that previous studies that have advocated a role for p wave signal 
averaging have been able to demonstrate a difference within a similar time scale. 
The equipment used during this study for the recording of p wave signal averaged 
ECGs included many of the optimum characteristics suggested by Ehlert et al for such 
systems. (126) It is therefore unlikely that a difference was not detected due to a lack of 
sensitivity of the analysis methods used. 
4.4 Heart rate variability 
Changes in the balance of activity within the autonomic nervous system are thought 
to play a part in the initiation of atrial fibrillation. The measured components of heart rate 
variability have been proposed as a means of studying this balance between the 
sympathetic and parasympathetic nervous system. The relative ease of recording of Holter 
recordings makes the concept of using heart rate variability measurements to predict 
relapse of atrial fibrillation attractive. However there are several problems with its use. The 
first problem encountered within this study related to the timing of the recordings. Ideally 
recordings should be made as soon as possible after sinus rhythm was achieved in order to 
avoid the problem of patients relapsing prior to heart rate variability measurements being 
completed. This must however be balanced against the potential for rate limiting 
medication to influence recordings. In our study not all patients were taking the same rate 
limiting medication at the time of cardioversion and hence heart rate variability 
measurement was only attempted after 48 hours of sinus rhythm free from rate limiting 
medication. This delay, although necessary, meant that heart rate variability could not be 
used to predict relapse occurring within the first forty eight hours post DC cardioversion. 
Another problem encountered with the time domain measurements compared within the 
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study was the lack of standardisation of patient activity during the recording period. Since 
patients were allowed home during the recording period patient activity could not be 
controlled for during the analysis. This may have masked any differences that were present 
and account for the negative results obtained. This was not a problem during the spectral 
domain recordings as all recordings were made under similar conditions and analysed as 
per the recommendations published by the European Society of Cardiology (130) There is 
little published literature on the use of heart rate variability following DC cardioversion 
and it is therefore difficult to determine whether a useful role exists or simply that we have 
been unable to demonstrate it here. Further work is required before a decision as to 
whether heart rate variability has a role in predicting relapse can be made. 
4.5 Relapse rates 
We have shown that DC cardioversion for chronic atrial fibrillation is a safe 
treatment option with no serious adverse effects occurring in any of the patients 
undergoing the procedure. The combination of transoesophageal echocardiography and DC 
cardioversion as a single "day case" procedure was found to be acceptable to all patients 
involved. 
As was expected DC cardioversion was initially successful in a high proportion of 
patients (8 1 %). Although this study was not specifically designed to compare different 
methods of performing DC cardioversion it would appear from our results that a starting 
energy of greater than I OOJ may allow a high success rate with a reduction in the number 
of shocks per patient. These results are consistent with those of Joglar et al who compared 
starting energy levels of I OOJ, 200J and 360J and concluded that higher success rates were 
achieved when a starting energy level of 360J was used. (58) 
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As in previous studies the rate of relapse following an initially successful procedure 
was highest at the beginning of the follow up period. When reviewed at forty eight hours 
35% of patients had relapsed to atrial fibrillation. Relapses continued to occur throughout 
the follow up period until at six months some 77% of patients had relapsed. These relapse 
rates are similar to those reported in previous studies. This means that 23% of patients who 
originally achieved sinus rhythm maintained a normal rhythm to six months. However 
when those patients who failed DC cardioversion are included this equates to 15 patients in 
sinus rhythm at six months from a total of 81 DC cardioversions. This is in fact a success 
rate of 18.5%. It can be seen from these figures that the prediction and if possible the 
prevention of early relapse to atrial fibrillation provides the greatest opportunity to 
intervene following cardioversion. However until a means of predicting relapse is available 
patient selection for DC cardioversion will remain a problem. The fact that cardioversion 
can be performed in any hospital setting, has a low complication rate and is well tolerated 
by most patients means that despite a low long term success rate it should continue to be 
offered routinely to patients with a first presentation of symptomatic chronic atrial 
fibrillation. The use of antiarrhythmic prophylaxis lowers the relapse rate but this is at the 
expense of potentially serious side effects. Given that nearly one in five patients will 
maintain sinus rhythm without antiarrhythmic prophylaxis it would seem reasonable at 
present to attempt DC cardioversion without prophylaxis and repeat the procedure with the 
addition of antiarrhythmics in patients who relapse and are symptomatic. 
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5 Conclusion 
This study represents one of the largest prospective trials to date aimed at 
elucidating the role of TOE, p wave signal averaging and heart rate variability in 
unselected patients with chronic non valvular atrial fibrillation. The safety of external DC 
cardioversion in conjunction with transoesophageal echocardiography is demonstrated by 
the absence of serious complications observed in this study population. 
The high relapse rates reported in this study highlight the potential advantage of 
being able to predict both initial success of DC cardioversion and subsequent relapse to 
atrial fibrillation. We have shown that transoesophageal echocardiography can be used to 
detect left atrial thrombi thus minimising the potential risk of thromboembolic 
complications with DC cardioversion. However transoesophageal echocardiography, p 
wave signal averaging and heart rate variability measurement proved to be unhelpful in 
predicting initial success of DC cardioversion. It can be concluded from the results of this 
study that transoesophageal echocardiography may have a role in predicting early relapse 
following successful DC cardioversion of chronic non valvular atrial fibrillation. No such 
role could be demonstrated for either p wave signal averaging or heart rate variability 
measurements. 
It is clear that further work is required to determine whether transoesophageal. 
echocardiography can be used to predict early relapse in a clinical setting. An intervention 
study with antiarrhythmic therapy guided by measurement of mitral valve flow velocity at 
transoesophageal echocardiography is required to detennine whether this would effect long 
term outcome. 
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7 Appendices 
7.1 Appendix I Patient information sheet 
PREDICTION OF SUCCESSFUL SINO-CONVERSION: PATIENT 
INFORMATION SHEET 
ABOUT THE STUDY 
You have been diagnosed as having a condition called atrial fibrillation. This is a 
condition in which the heart rhythm becomes irregular due to disordered electrical activity 
in the smaller chambers of the heart called the atria. 
Atrial fibrillation increases the risk of small blood clots forming in the atria which 
may lead to further complications. 
The best treatment for this condition is to restore the heart to its normal rhythm. 
However at present it is not possible to predict which patients will have further episodes of 
atrial fibrillation. This study will attempt to do this. 
If you decide to take part in this study you will be treated for your atrial fibrillation 
in the usual way as will be explained below. Participation in the study will involve regular 
follow up at the outpatient department and a series of recordings of the heart being taken 
similar to the ECG you have already had. 
The treatment for your atrial fibrillation will include an investigation called a 
transoesophageal echocardiogram and a procedure called a cardioversion. 
WHAT IS A TRANSOESOPRAGEAL ECHOCARDIOGRAM? 
A transoesophageal echocardiograrn (TOE) is a simple development of ultrasound. 
To perform a TOE a probe is passed down the gullet to sit just behind the heart and 
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pictures of the heart are taken which allow the structure of the heart to be identified. It also 
allows the atria to be visualised more accurately to ensure that no blood clots have formed 
within the heart. For the purpose of this study we will take extra measurements of the heart 
during the procedure. 
HOW IS A TOE PERFORMED 
After having nothing to eat or drink for six hours, you will attend the coronary care 
unit. A small cannula will be inserted into a vein in the back of your hand and a sedative 
will be administered through it. You will not be fully asleep but you will be drowsy. Local 
anaesthetic will be sprayed into the back of your throat, once it has gone numb you will be 
asked-to swallow the TOE probe. Most people manage this quite easily. Once the probe 
has been passed down to behind the heart the pictures are taken. The procedure takes about 
twenty minutes. 
if the procedure does not show any sign of blood clots in the heart you will go on 
to have a cardiovcrsion as outlined below. 
However if the test reveals that a blood clot has fonned the cardioversion would be 
postponed and you will be allowed to recover from the sedative. You will need about 90 
minutes to recover from the sedative. The result will be explained to you and you will be 
given something to eat and drink prior to being allowed home. You should have someone 
to escort you home. You should not drive or drink alcohol on the day of the procedure. 
WHAT IS A CARDIOVERSION? 
A D. C. cardioversion is a method of restoring your heart to its natural rhythm by 
using an electric current. 
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HOW IS IT PERFORMED? 
To perform the cardioversion you will be sedated further, by an anaesthetist, until 
you are fully asleep. When you are fully asleep a very brief electric current will be applied 
to your chest to restore the heart to its natural rhythm. You will then gradually come round 
from the anaesthetic. It usually takes a few hours to fully recover, after which you will be 
given something to eat and drink. You should not drive for at least six hours and should 
organise for someone to accompany you home. 
Following a successful restoration of your normal heart rhythm you may be able to 
stop taking some of your medication, however you should continue to take warfarin for a 
further month. 
On the day of your cardioversion you will have a special type of heart recording 
called a signal averaged ECG. This is similar to the normal ECG that you have already had 
but takes around thirty minutes to complete. 
You will then be seen in the outpatient clinic after about two weeks and an ECG 
of the heart taken to check that it has remained in its normal rhythm. A signal averaged 
ECG will also be recorded at this visit. This will take about one hour and will be perfonned 
in the ECG department. You will also be fitted with a device, which is wom on a belt 
around the waist, which will record your heart rate over the next 24 hours. You should 
return this machine the following day to the ECG department. You do not need to be fasted 
for any of these tests to be carried out. 
Following this you will be seen at the outpatient clinic every three months for a 
period of at least 12 months to check on your progress. 
If you have any questions or problems with the above you can contact Dr Runnett 
(ext. 2593) or Dr Doig at North Tyneside General Hospital. 
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7.2 Appendix 2 Patient consent form 
CONSENT FORM 
STUDY OF ATRIAL FIBRILLATION AND PREDICTION OF SUCCESSFUL SINO- 
CONVERSION 
I have been given the patient information sheet regarding this study and have had the 
chance to think about participation. I have had my questions answered and understand 
what is involved in participation. I understand that if I choose not to take part that my 
medical care will not be affected by this decision and that if I choose to take part I can 
withdraw at any stage with no penalty. 
I understand that any claim for damages against Northumbria Healthcare Trust will be 
covered by the NHS indemnity policy in the usual way. 
I am willing to take part in this research project 
I do not wish to take part in this research project 0 
I would like more time to think about it 0 
Patient: 
Name 
Signature 
Witness: 
Name 
Signature 
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